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Retroviruses exhibit high mutation rates.  High mutation and recombination rates increase 
variation within a viral population and result in production of drug-resistant mutants 
and/or mutants that can escape a host immune response.   Mutations are introduced into 
the viral genome by error-prone reverse transcriptase (RT), a virally encoded enzyme that 
converts single-stranded viral RNA into double-stranded DNA.  In the current study we 
are trying to understand what structural determinants of RTs are important for fidelity, 
frequency of template switching, and drug-resistance.  First, we developed an in vivo 
assay and performed mutational analysis of murine leukemia virus (MLV) RT to identify 
structural elements important for template switching.  Based on obtained results, we 
proposed a dynamic copy-choice model in which both the rate of DNA polymerization 
and the rate of degradation of the RNA template influence the frequency of RT template 
switching.  Second, we employed a previously described in vivo fidelity assay to 
determine whether a minor groove binding helix of the thumb domain and primer grip of 
MLV RT are important for in vivo fidelity of reverse transcription.  Because the thumb 
domain of MLV RT has not been crystallized, we utilized homology alignment and 
molecular modeling to identify the minor groove binding helix of the thumb domain of 
MLV RT.  Mutations in the minor groove binding helix residues R301 and F309 
decreased RT fidelity by up to 2.8-fold, suggesting that this region plays an important 
role in accuracy of DNA synthesis.  Finally, we attempted to elucidate a mechanism of 
drug-resistance to the antiretroviral nucleoside analog 2′,3′-dideoxy-3′-thiacytidine 
(3TC), an inhibitor of wild-type human immunodeficiency virus type 1 (HIV-1) RT.  We 
tested our hypothesis that a valine residue at the 223 position in YVDD motif of the MLV 
RT leads to a natural high level of resistance of MLV to 3TC in a manner similar to that 
proposed for the YVDD mutant of HIV-1 RT.  The results indicated that the wild-type, 
V223M, V223I, V223A, and V223S mutants of MLV RT were all highly resistant to 
3TC, suggesting that determinants outside the YVDD motif of MLV RT confer a high 
level of resistance to 3TC.   
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Approximately 34 million people worldwide are currently infected with human 
immunodeficiency virus type-1 (HIV-1) (1).  The vast majority of these individuals are 
destined to die of acquired immunodeficiency syndrome (AIDS) unless truly effective 
therapy can be developed (74).  For them, as well as many more who will become 
infected within the next few years, any future vaccine will come too late, and effective 
therapy must be developed to combat existing infection.  The recent application of 
therapies using combinations of antiviral drugs has shown that virus growth in infected 
people can be brought to an undetectable level and, in many individuals, provide 
considerable and long-lasting improvement in their condition (6).  These therapies have 
helped large numbers of people live relatively normal lives despite their HIV-1 infection; 
however, these drugs do not provide a long-term solution.  The problem is in the 
development of resistant viral variants due to the appearance of specific mutations (6).  In 
an effort to avoid resistance, drugs have to be given at high toxic doses and in expensive 
combinations.  Even then, the therapy often fails, and resistant virus appears.  There is, 
therefore, a desperate need to understand how the virus develops resistance to drugs, and 
to use this understanding to develop more effective strategies for treating HIV-1 
infection. 
Retroviral life cycle.   HIV-1 belongs to retroviruses, a family of RNA viruses that 
replicate via a DNA intermediate (15).  A schematic representation of the retroviral 
replication cycle is shown in Fig. 1 (15, 52, 69).  Initiation of retrovirus replication 
involves a highly specific interaction between a virion envelope proteins with a cell-
surface receptor.  The virus envelope and the cell membrane fuse to release the viral core 
into the cytoplasm.  After entry of the core into the cytoplasm, the RNA genome is 
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reverse transcribed into double-stranded DNA.  Integration of the viral DNA into random 
sites in the cell chromosome forms the provirus.  Viral RNA is synthesized by cellular 
RNA polymerase II which uses the integrated provirus as a template.  Synthesis of viral 
proteins is followed by formation of viral particles at the plasma membrane.  The viral 
RNAs, which have a special encapsidation signal (named the ψ-region), can be packed 
into virus.  The newly made virion can then repeat the cycle by infecting other cells.    
Mutations could be possibly introduced into retroviral genome at three different 
steps of viral replication.  First, the reverse transcriptase (RT), a virally encoded enzyme, 
can potentially introduce mutations into the viral genome during the process of reverse 
transcription, which involves both RNA- and DNA-dependent DNA syntheses.  The 
mutation rate of RTs was estimated to be around 10-5 mutations per base pair per 
replication cycle (41, 42, 51, 53-55, 58). Second, cellular DNA polymerases replicate the 
provirus in each cell cycle and also could mutate proviral DNA.  However, cellular DNA 
polymerases possess proofreading mechanisms and as a result cellular DNA replication 
has very low mutation rates (10-9 to 10-11 substitutions per base pair per cell division). 
Therefore, it is unlikely that cellular DNA polymerases are the major contributors to 
mutations introduced in the retroviral genome.(25).  Finally, RNA polymerase II 
synthesizes the RNA genome of the next generation of virions.  Fidelity of RNA 
polymerase II was recently measured in vitro to be between 10-3 and 10-5 
misincorporations / bp / cycle (46).  These data provide a large range for the fidelity of 
RNA polymerase II.  More recent studies indicate that this measurement was an 
overestimate of the RNA polymerase II mutation rate.  Because the mutation rates of RT 
and RNA polymerase are comparable it is not clear which of the enzymes contributes to 
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retroviral mutation rate the most.  To sort out these possibilities it has been recently 
shown that at least one third of the retroviral mutations (32%) are introduced into a 
retroviral genome during plus-strand synthesis and approximately two third of mutations 
(68%) are introduced during minus-strand synthesis and RNA transcription (37). These 
data indicate that the RNA polymerase II mutation rate cannot be grater than 2/3 of the 
retroviral mutation rates (1x10 –5 / bp / replication cycle).  Mutations that occur during 
DNA dependent DNA synthesis result in mismatches.  Recent studies have indicated that 
mismatches involving large loops can be efficiently repaired by the host repair system 
affect the overall mutation rate (11).   
Reverse transcription.  Reverse transcription is a process in which the viral RNA is 
copied into a double-stranded DNA (Fig. 2) (24, 52).  In the initial step of reverse 
transcription, a tRNA primer associates with RT at the primer-binding site (PBS) near the 
5’ end of viral RNA, is utilized to synthesize the short piece of DNA.  This short piece 
DNA is called the minus-strand strong-stop DNA.  Along with synthesis, the RNase H 
activity of RT degrades the RNA template in RNA-DNA hybrids approximately 18 bases 
behind the 3’OH of the primer.  Once the synthesis of the minus-strand strong-stop DNA 
is accomplished, the minus-strand strong-stop DNA is transferred to the 3’ end of the 
viral RNA using complementarity of the terminal repeat (R) regions.  Consequently, the 
minus-strand strong-stop DNA is extended to form the minus-strand DNA. The minus-
strand DNA is also accompanied by RNase H degradation of the RNA template.  The 
RNA sequence named polypurine tract (PPT) is resistant to complete RNase H 
degradation and forms a specific primer for initiation of plus-strand synthesis.  The plus-
strand DNA synthesis is initiated by synthesizing of a piece of DNA called plus-strand 
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strong-stop DNA.  The plus-strand strong-stop DNA ends with a PBS sequence as a 
result of copying 18 bases of tRNA.  It has been proposed that copying of the tRNA ends 
at the first modified base of the tRNA.  The plus-strand strong-stop DNA is transferred to 
the 5’ end of the viral DNA by complementation at the PBS.  DNA synthesis continues in 
both directions to complete the synthesis of viral DNA.  As a result of reverse 
transcription, the viral double-stranded DNA has long terminal repeats (LTRs) at both 
ends.  LTRs consist of U3 (unique 3’), R, and U5 (unique 5’) regions.  By using the 
LTRs, the double-stranded DNA integrates into the host chromosome to form a provirus.   
Crystal structure of RTs.  Several crystal structures of HIV-1 RT have been reported, 
including co-crystals with non-nucleoside inhibitors, DNA, and a ternary complex with 
bound DNA and a substrate dTTP (17, 31, 38, 65).  The enzyme is a heterodimer 
composed of 66 and 51 kD subunits (Fig. 3A).  The structure of p66 subunit resembles a 
right hand and is referred to as the fingers, palm, connection, thumb, and the RNase H 
domains (17, 31, 38, 65).  The thumb domain consists of a bundle of α-helixes.  The p51 
subunit is composed of four domains referred to as fingers, thumb, palm, and connection.  
Only the p66 subunit possesses the polymerization and RNase H activities (38).  The 
highly conserved YMDD motif constitutes the active site of the enzyme (32).  The  β12-
β13 hairpin is thought to act as the primer grip and is important for positioning the 3’ OH 
of the primer into the active site of the RT.  The highly conserved LPQG box has been 
proposed to form hydrogen bonds with the incoming dNTP and the template (61).  
Recently, a crystal structure of a ternary complex of HIV-1 RT with bound DNA and a 
substrate dTTP (Fig. 3B) (31) was solved.  This structure revealed detailed interactions of 
RT with template-primer complex as well as dTTP substrate.  For example, all amino 
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acids that form dNTP-binding pocket were identified.  Amino acids K65, R72, D113, 
A114, Y115, and Q151 were shown to directly interact with the incoming dNTP.  It was 
also shown that the α-helix H of the thumb domain fits into the minor groove of the 
template-primer complex and form interactions with the second, third, and forth bases 
upstream of the 3’ end of the primer.  More excitingly, using these crystal structure data it 
became possible to measure any distances within this ternary complex.   
The crystal structure of an MLV RT fragment (amino acids 24 - 274) consisting 
of the fingers and palm domains has also been determined (23).  The MLV RT is a 75 kD 
monomer that has been proposed to form a homodimer in the presence of substrate (68).  
The fingers and palm domains of this crystallized fragment fold in a very similar manner 
as the fingers and palm domains of HIV-1 RT.  Even though HIV-1 and MLV RTs share 
only 25% sequence identity, their overall folds in the fingers and palm domains are 
incredibly similar (64, 73).  Recently, crystal structures of the same fragment containing 
the fingers and palm domains of MLV RT were obtained in the presence of DNA (47).  
These structures showed a different form of DNA binding in comparison to HIV-1 RT.  
These differences are likely to be explained by the absence of the thumb domain in the 
crystallized fragment of MLV RT, which was shown previously to be important for 
proper binding of the template-primer complex.   
High frequency of large direct repeat deletion by RTs.  Previous studies have shown 
that directly repeated sequences found in retroviral vectors and genomes tend to be highly 
unstable (34, 49) and are believed to be deleted through the normal process of reverse 
transcription.  For example, deletions studied in SNV have shown that direct repeats of 
1333, 788, and 383 bp were deleted at frequencies of 93%, 85%, and 40% respectively 
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(34).   The template misalignment model has been proposed to explain the phenomena of 
direct repeat deletion in retroviruses (34). Recent data has indicated that direct repeat 
deletions occur nearly at the same rate during RNA-dependent and DNA-dependent DNA 
synthesis (49).  
A modified template misalignment model of direct repeat deletion is shown in 
Fig. 4 (16).  The model proposed that base-pairing between newly synthesized DNA 
sequences 3′ to the RT with complementary sequences of the template increases the 
probability of RT switching templates.  As RT copies the 3′ direct repeat, RNase H 
degrades the RNA template 3′ to the RT.  Subsecuently, hydrogen bonding occurs 
between the newly synthesized single-stranded DNA and complementary sequences in 
the 5′ copy of the direct repeat.  The conformational rearrangements that permit this 
hydrogen bonding are depicted as a loop in the template RNA in Fig. 4.  The hydrogen-
bonding interactions 3’ to the RT bring the homologous acceptor template in close 
proximity to the RT, subsequently leading to a template switch. 
The frequency of direct repeat deletions may be used to estimate the processivity 
of RTs.  Lower processivity of RT results in more frequent dissociation from the template 
and consequently higher frequency of direct repeat deletions.  It is likely that mutations in 
RT that affect processivity affect the frequency of template switching; however, 
structural determinants of RTs that are important for direct repeat deletions and template 
switching remain to be identified.  The direct repeat deletion assay in vivo can provide a 
powerful model to identify these determinants. 
Assays for measurement of the fidelity of RTs.  The fidelity of RTs can be measured 
by utilizing purified RT with a template-primer and appropriate dNTPs.  This kind of 
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assay would be considered an in vitro assay.  These reactions are usually performed on 
templates that are different from the templates used by RT during viral reverse 
transcription and at different reaction conditions such as dNTP concentration, Mg2+ 
concentration, and pH (13, 19, 43).  Additionally, the fidelity of DNA polymerases may 
be altered by purification procedures trough proteolytic loss of the proofreading domain 
(39, 56).  As a result, RT fidelity measured in an in vitro assay may be significantly 
different from RT fidelity during reverse transcription.  The estimation of the RT fidelity 
of the replication-competent virus in vivo was difficult because the number of replication 
cycles were not known.  The approach of the packaging cell line, which allows 
production of virus capable of infecting target cells only once, has been developed.    The 
one cycle replication assays can be used to measure the rate of mutations introduced by 
the RT in a reporter gene during reverse transcription in vivo (41, 42, 53, 54).  
Comparison of HIV-1 in vitro and in vivo mutation rates indicated that the in vitro error 
rates were 16-20 fold higher than the in vivo mutation rate (41).   
 Recently, an in vivo fidelity assay was developed to study structural determinants 
that are important for fidelity (27).  First, ANGIE P encapcidating cell line was 
developed.  To develop the ANGIE P, a MLV cell line retroviral genome was divided 
into three constructs: pLGPS that expressed gag-pol retroviral proteins; pA-MLVenv that 
expressed the amphotropic MLV envelope; and retroviral vector pGA-1 that encoded all 
cis-acting elements necessary for packaging of viral RNA and completion of reverse 
transcription (Fig. 5).  In addition, the retroviral vector pGA-1 encoded the β-
galactosidase reporter gene and neomycin resistance gene.  The ANGIE P cell line was 
developed by stable transfection of D17 cells with pA-MLVenv and retroviral vector 
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pGA-1.  Upon transfection of wild type or RT mutant pLGPS construct into ANGIE P 
cells, the cells produced virus that contain wild type or mutant RT and GA-1 viral RNA 
(Fig. 6).  The collected virus was used to infect target cells.  During reverse transcription 
mutations were introduced into β-galactosidase reporter gene by wild type or mutant RT 
and visualized by staining the infected cells with X-Gal, a color substrate for functional 
β-galoctosidase.  Blue colonies contain no inactivating mutations in β-galoctosidase, 
where as white colonies contain an inactivating mutation in β-galactosidase.  Comparison 
of the frequencies of the white and blue colonies for wild type RT and mutant RT 
provided an estimation of the effect of a particular mutation on RT fidelity. 
Structural determinants of the RT that are important for fidelity.   The genetic 
variation in retroviral populations is generated by their high rates of mutations and 
recombination (14, 29, 30, 41, 42, 51, 53-55, 57, 70).  There are two possible 
explanations for the low fidelity of RTs.  First, low processivity of RT was likely to be 
selected by evolution because it is essential for the process of reverse transcription.  The 
RT needs to be easily dissociated from the template in order to accomplish the minus-
strand and plus-strand transfer events that are necessary for completion of reverse 
transcription (70).  Second, it was postulated that RT lacks proofreading activity.  
However, currently this statement is being questioned.  It was found that HIV-1 develops 
resistance to the 3'-azido-3'-deoxythymidine (AZT), a nucleoside analog that inhibits 
reverse transcription by termination DNA polymerization reaction because it lacks the 3’ 
OH (3, 4).  Resistance to AZT is associated with the ability of the drug-resistant mutant 
of the HIV-1 RT to remove the incorporated AZT from the 3’ end of the synthesized 
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DNA.  This activity is mainly associated with a drug-resistant RT mutant, but wild type 
HIV-1 RT is also capable of performing this reaction, although less efficiently (3, 4).    
Structural determinants of RT that are important for accuracy of the enzyme are 
currently unknown.  Based on the crystal structure of the RT and experimental evidence 
it was proposed that the YXDD box, the LPQG box, the dNTP binding site, the α-helix H 
of the thumb domain, and the RNase H domain may play a role in the fidelity of RT.  
Each of these domains are briefly discussed bellow. 
YXDD box:   Experimental evidence supports that the YXDD box is important for 
fidelity.  Mismatch extension assays performed in vitro showed that the M184V mutation 
of the YXDD box increases fidelity of the HIV-1 RT (72).  The same result was 
reproduced by another research group which demonstrated that the order of accuracy of 
184 variants in vitro is Ile>Val>Met (50).  However, in vivo studies did not show a 
significant change in fidelity for M184V (48).  In addition, an M13 phage-based forward 
mutation assay indicated that M184V and E89G mutants, as well as double mutant 
(M184V/E89G), do not have a significant change in fidelity as shown in vitro (18).  This 
result is in agreement with in vivo data from our laboratory, which indicates that the 
difference in fidelity between M and V variants of YVDD box of MLV RT is not more 
than two fold (27).  Additionally, other mutants showed that the order of fidelity in vitro 
is M184L>Y183F>WT HIV-1 RT (5).  Other studies of mutants of YXDD box have 
indicated M184I and M184V display a slight reduction in processivity and the M184L 
and M184A mutants show considerable reduction in processivity (12). 
Thumb domain:  The amino acids of the α-helix H of HIV-1 RT were mutated one by 
one to alanines and fidelity and template-primer binding of constructed mutants were 
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tested in vitro.  The results showed that G262A and W266A possess low fidelity and 
were demonstrated to be important for primer-template binding (7).  Another in vitro 
study confirmed this result exhibiting lower processivity and lower fidelity of the G262A 
and W266A mutants by comparison with wild type HIV-1 RT (8). 
dNTP binding site:  The F155 of the dNTP binding site of MLV RT was proposed to 
play a role in discrimination between incoming dNTPs (20, 44, 45, 61).  Fifteen  mutants 
at position Y115 showed a decreased fidelity in vitro indicating the importance of the 
dNTP binding site for accuracy of DNA synthesis (44, 45).  The position 155 is a part of 
the dNTP binding site of MLV and is analogous to Y115 in HIV-1 RT.  Recently, the 
role of this and other residues of MLV RT were studied in an in vivo fidelity assay.  The 
results indicated that most of the mutants of the dNTP-binding site of MLV RT resulted 
in noninfectious virus.  The mutants with a detectible titer deceased fidelity up to 2-fold 
(28).   
RNase H:  RNase H mutations affect RT processivity and interactions of the RT with its 
template, which may alter the fidelity of RT (68).  Additionally, the RNase H domain is 
believed to play an important role in template-switching events, which result in deletions 
and insertions during reverse transcription (22, 34, 40).  The S526A, R657S, and Y598V 
mutations of MLV RT were tested in an vivo fidelity assay in our laboratory. The S526A 
and R657S RNase H mutants showed approximately 1.4- and 1.2-fold increases in mutant 
frequency, respectively (27). 
Other regions:  Some other specific residues of HIV-1 RT have been shown to affect 
fidelity in vitro.  E89G, a nucleoside analog-resistant variant of HIV-1 RT, exhibited 2-17 
fold increase in fidelity in vitro (18).  This result was confirmed by another in vitro study 
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indicating the order of fidelity of drug-resistant variants to be E89G>L74V>WT HIV RT 
(59).  However, the HIV-2 mutants did not show a significant increase in fidelity: the 
E89G mutant showed some enhanced fidelity, but L74V, in contrast to HIV-1, has 
showed a fidelity similar to that of wild type HIV-2 (67).  Additionally, the importance of 
the F160, D76, and  L74 of HIV-1 RT for fidelity was studied. The F160W mutant 
displayed a slightly higher fidelity, but it was shown only in vitro at a high dNTP 
concentrations (26).  The D76V resulted in a 14-fold increase in fidelity in vitro (36). The 
L74V resulted in a 3.5-fold higher fidelity in vitro (33, 63).   
Mechanisms of resistance to 3TC.  Two viral enzymes, RT and protease, are the most 
common targets for the anti-retroviral drugs.  Drug treatment invariably results in the 
selection of drug-resistant variants that are already present in the viral population.  There 
are two classes of RT inhibitors: nucleoside analogs and non-nucleoside inhibitors.  
Nucleoside analog RT inhibitors lack the 3’OH of the ribose ring.  In the cytoplasm of the 
target cell, nucleoside analogs are converted into nucleoside-analog triphosphates which 
are consequently incorporated into viral DNA by HIV-1 RT and, as a result, cause the 
termination of DNA polymerization.  Treatment of HIV-1 infected patients with 2′,3′-
dideoxy-3′-thiacytidine (3TC), a nucleoside analog inhibitor of HIV-1 RT, results in the  
selection of drug-resistant variants with changes at position 184 of the YMDD motif (9, 
21, 35, 62, 71).  Usually the variant M184I appears first and then is replaced by the 
M184V variant (10).   Viruses carrying either of these mutations are very resistant for 
3TC in vivo and in vitro.  Structural analyses have provided models to explain the high 
level of resistance of the M184I and M184V mutants for 3TC.  The combination of 
introducing a sulfur atom into the ribose ring and choosing the opposite orientation causes 
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the portion of the modified ribose ring that carries the sulfur atom to project farther than 
the normal ribose ring, thus creating an opportunity for steric hindrance (structure of 3TC 
is shown in Fig. 7) (60).  The inhibition of the wild-type enzyme by 3TC suggests that 
3TC easily incorporates without significant steric hindrance with methionine at position 
184.  On the other hand, based on the molecular modeling of 3TC-resistant variants of 
HIV-1 RT, a β-branched amino acid, such as I or V, at position 184 would interfere with 
the ability of  3TC triphosphate  to bind in the correct orientation at the RT active site (60).  
This hypothesis also might explain the natural resistance to 3TC of variants of feline 
immunodeficiency virus that have another β-branched amino acid residue (threonine) at a 
position equivalent to 184 of HIV-1 RT (66) and the resistance of hepatitis B virus MLV 
RT  (2) with either valine or isoleucine at the position equivalent to 184 of HIV-1 RT.  
Overview of thesis.   The purpose of the current work was to elucidate structural 
determinants that are responsible for the high frequency of template switching and the 
low fidelity of RT as well as to understand the mechanisms of development of drug-
resistance by RTs.  In chapter 2, we discuss how mutations of the YXDD motif, the 
dNTP-binding site, the thumb domain, and the RNase H domain of MLV RT affect the 
frequency of template switching during reverse transcription in vivo.  Based on the 
results, we proposed a dynamic copy-choice model in which both the rate of DNA 
polymerization and the rate of degradation of the RNA template influence the frequency 
of RT template switching.  The third chapter is devoted to understanding whether a minor 
groove binding helix of the thumb domain and primer grip of MLV RT are important for 
in vivo fidelity of reverse transcription.  Homology alignment and molecular modeling 
was utilized to identify the minor groove binding helix of MLV RT thumb domain.  
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Finally in chapter 4, we attempt to dissect the mechanism of drug-resistance to 3TC.  We 
test a hypothesis that the presence of a valine residue at 223 position in YVDD motif of 
the MLV RT leads to a natural high level of resistance of MLV RT to 3TC in a manner 
similar to that proposed for YVDD mutant of HIV-1 RT.  In chapter 5 we discuss how 
these studies contributed to the overall knowledge of retroviruses and future experiments 
that could be done to further investigate mechanisms of generating high genetic variation 
in retroviral populations.     
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Figure 1.  Retroviral replication cycle.  Steps in replication designated by numbers as 
follows: entry (1), minus-strand synthesis (2), plus-strand synthesis (3), integration (4), 
replication as a provirus by cellular polymerases (not required) (5), transcription (6), 
translation (7), assembly, packaging, and budding (8).  
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Figure 2.  Reverse transcription. Taken from ref. 52. Thin line represents RNA, bold 
line represents DNA, and dashed lines represent RNase H degradation.  A zigzag line 
represents tRNA primer.  
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Figure 3.  Crystal structure of HIV-1 RT.  (A) The p66 subunit consists of the fingers, 
palm, thumb, connection, and RNase H domain.  Figure was modified from ref. 32.  (B) 
Crystal structure of HIV-1 RT bounded to DNA.  Figure was modified from ref. 30. 
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Figure 4.   Model for direct repeat deletions during reverse transcription.  Shaded 
boxes represent direct repeats.  Horizontal arrows represent nascent DNA.  Dashed lines 
represent degraded RNA by the RNase H domain.  Hydrogen bonds between the RNA 
template and nascent DNA are designated by vertical marks.  (1) RT copies the 3′ direct 
repeat, (2) RNase H degrades the RNA template 3′ to the RT.  Subsecuently, hydrogen 
bonding occurs between the newly synthesized single-stranded DNA and complementary 
sequences in the 5′ copy of the direct repeat.  The conformational rearrangements that 
permit this hydrogen bonding are depicted as a loop.  (3) The hydrogen-bonding 
interactions 3’ to the RT bring the homologous acceptor template in close proximity to 
the RT, subsequently leading to a template switch.  (4) Final product contains only one 
copy of direct repeats. 
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Figure 5.  Strategy of construction of ANGIE P cell line.  (A) Structure of retroviral 
genome, retroviral vector GA-1. LTR-long terminal repeats; LacZ - β-galoctosidase gene; 
neo – neomycin resistance gene; pLGPS – gag-pol expressing construct; pA-MLVenv – 
amphotropic MLV envelope expressing construct; ψ - packaging signal.  (B) ANGIE P 
cell line. 
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Figure 6.  In vivo fidelity assay.  All abbreviations are as described for Fig. 5.  
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Figure 7.  Structure of deoxycytidine and  2′,3′-dideoxy-3′-thiacytidine (3TC). 
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ABSTRACT 
 Retroviral reverse transcriptases (RTs) frequently switch templates 
within the same RNA (intramolecular) or between copackaged viral RNAs 
(intermolecular).  Template switching by RT is necessary for completion of 
reverse transcription and results in the generation of mutations and 
recombination, which increase variation in retroviral populations.  The 
structural features of retroviral RTs that affect the frequency of template 
switching are currently unknown.  To identify structural elements of murine 
leukemia virus (MLV) RT important for template switching, we developed an in 
vivo assay.  This assay used a retroviral vector encoding directly repeated 
sequences composed of overlapping fragments of the green fluorescent protein 
gene (GFP) that was permitted to undergo one round of reverse transcription.  
Template switching within the direct repeats functionally reconstituted GFP.  
We quantified the effect of mutations in RT on the frequencies of template 
switching.  Using MLV RTs containing single amino acid substitution mutations 
in the Tyr-X-Asp-Asp (YXDD) motif, the dNTP binding site, the thumb domain, 
and the RNase H domain were characterized.  The results showed that some 
mutations in the YXDD motif and dNTP binding site increased the frequency of 
template switching, while all mutations in the RNase H domain tested decreased 
the same frequency.  Hydroxyurea treatment, which depleted nucleotide pools 
and reduced the rate of DNA synthesis, increased the frequency of template 
switching for the wild-type RT and the YXDD mutant RTs, but not for the 
RNase H mutant RTs.   Based on these results, we proposed a dynamic copy-
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choice model in which both the rate of DNA polymerization and the rate of 
degradation of the RNA template influence the frequency of RT template 
switching.     
INTRODUCTION 
 The process of retroviral reverse transcription requires the dissociation of nascent 
DNA from one location on the RNA template and reassociation of the DNA at another 
region of homology (11).  The first of these template-switching events, minus-strand 
DNA transfer, involves the transfer of the minus-strand strong-stop DNA from the 5′ end 
of the viral genomic RNA to the 3′ end of the RNA using the two identical R regions at 
the ends of the viral RNAs.  The second template-switching event, plus-strand transfer, 
involves the transfer of the plus-strand strong-stop DNA using the complementarity 
between the primer tRNA and the primer binding site.  It has been hypothesized that 
because these template-switching events are necessary for the completion of viral 
replication, retroviral RTs have evolved to possess low template affinity and low 
processivity (63).  Since RTs possess low processivity, they also frequently undergo other 
internal template-switching events during reverse transcription.  Intermolecular template-
switching events between copackaged viral RNAs can result in homologous and 
nonhomologous recombination (24, 35, 64).  On the other hand, intramolecular template-
switching events (within the same template) generate mutations such as deletions, 
deletions with insertions, and duplications (44, 46). 
 Retroviral vectors containing directly repeated sequences provide a powerful in 
vivo experimental model system for elucidating the mechanism of RT template switching 
(14, 32, 46, 70).   Directly repeated sequences delete at a high frequency (8, 12, 13, 26, 
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35, 42, 46, 47, 67), which appears to be correlated with the size of the repeats (13, 32, 48, 
71).  Deletion of direct repeats is a highly accurate process, because drug resistance genes 
and other selectable markers are functionally reconstituted with a high efficiency (13, 
32).  It was also recently shown that the linear distance between direct repeats increased 
the frequency of deletions and that within a 701-bp direct repeat, the frequency of 
template switching was higher near the 5′ end of the repeat than the 3′ end (14).  These 
results suggested that the length of homology 3′ to the site of polymerization was 
important for efficient template switching.  These data also suggested that degradation of 
the template RNA with RNase H permitted base pairing between the repeated sequence 
to facilitate RT template switching and deletion.   
 Structural features of RTs that may play an important role in their template- 
switching properties are currently unknown.  Previous studies have indicated that RNase 
H activity is necessary for minus-strand transfer as well as plus-strand transfer (16, 54, 
60, 61).  Mutations in several regions of RT have been shown to affect processivity of 
DNA synthesis in vitro; these regions include the Tyr-X-Asp-Asp (YXDD) motif (9, 22, 
53), the thumb region (2, 3, 5), the fingers domain (52, 59), residue Q151 of the dNTP 
binding site (30), and the RNase H domain (1, 62).  In addition, other viral proteins, 
specifically, the nucleocapsid protein (NC) might be important for template switching.  
Some in vitro studies have suggested that NC increases the processivity of RT (15, 29).  
However, other studies have indicated that NC has no effect on the processivity of RT 
(49, 50). 
 To identify the structural determinants of RT that are important for template 
switching, we introduced amino acid substitutions in the murine leukemia virus (MLV) 
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RT dNTP binding site, the YXDD motif, the α-helix H of the thumb domain, and the 
RNase H domain.  We also developed an in vivo assay and determined the extent to 
which the mutations in RT affected the frequency of template switching.  These results 
show that the dNTP binding site, the YXDD motif, the α-helix H of the thumb domain, 
and the RNase H domain of RT can influence template switching. 
MATERIALS AND METHODS 
Plasmids.   Plasmid pLGPS expressed the MLV gag and pol genes from a 
truncated MLV long terminal repeat (∆ LTR) promoter (41).  The plasmid pSV-A-MLV-
env, which expressed the amphotropic MLV envelope gene from the long terminal repeat 
(LTR) promoter and SV40 enhancer, was obtained from the AIDS Research and 
Reference Reagents Program (39).  The plasmid pBSpac encoded the puromycin N-
acetyltransferase gene and conferred resistance to puromycin (66).  The plasmid pSVα3.6 
encoded the α subunit of the murine Na+, K+-ATPase gene and conferred resistance to 
ouabain (36).  Plasmid pGA-1, a MLV-based retroviral vector, encoded the neomycin 
phosphotransferase gene (neo) as well as the β-galactosidase gene (33).  
Construction of retroviral vector pES-GFFP.  The MLV-based retroviral 
vector pES-GFFP was constructed using standard cloning procedures (51).  Plasmid 
pGF100FP–Mlu was constructed from pGF100FP.  The construction of pGF100FP was 
based on the parent vector pWH390-Cla (13).  Plasmid pWH390-Cla was digested with 
EcoRI and a polylinker containing BglII, NruI, BamHI, StuI, and SalI was inserted, which 
regenerated the EcoRI site at the 3’ end, forming pCH-L1.  Plasmid pGL-1 [pGreen 
Lantern-1, encoding the green fluorescent protein (GFP)] (Gibco BRL) was digested with 
SpeI and BstBI, and the 363-bp fragment designated GF was inserted into the NruI site in 
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pCH-L1, generating pVVCH-GF.  The FP fragment (486 bp) containing a 100-bp direct 
repeat with GF was PCR amplified from pGL-1 (primer sequences available upon 
request).  The FP fragment was inserted into the StuI site in pVVCH-GF generating 
pGF100FP.  To construct pGF100FP-Mlu, pGF100FP was partially digested with BamHI 
and a linker containing a unique MluI site flanked by two XhoI sites was inserted between 
the GF and the FP fragments.  Plasmid pGF100FP-Mlu was cut with BglII plus MluI and 
treated with calf intestinal phosphatase plus the Klenow fragment of DNA polymerase I 
to generate dephosphorylated blunt ends.  Plasmid pGL-1 was cut with HincII, and the 
resulting 521-bp fragment was ligated into the backbone vector.  The correct structure of 
the resulting pES-GFFP plasmid was confirmed through restriction enzyme mapping.  
  Generation of MLV RT mutants.  Construction of the dNTP binding site, 
YXDD motif, and the RNase H mutants of MLV RT was described previously (20, 21).  
A detailed description of the mutagenic oligonucleotides and the strategies used to 
introduce mutations in the α-helix H  of the thumb domain is available in Appendix 2.  
Briefly, the mutagenic oligonucleotides were designed to introduce additional silent 
mutations and generate new restriction sites.  Restriction digestion analysis was 
performed to identify plasmids containing mutations, and DNA fragments containing the 
mutations were subcloned into pLGPS.  The inserted fragments were analyzed by DNA 
sequencing to verify the presence of the desired mutation and the absence of undesired 
mutations (ALF Automated Sequencer, Pharmacia). 
 Cells, transfections, and infections.  D17 dog osteosarcoma cells (obtained from 
American Type Culture Collection) were transfected, infected, and selected for resistance 
to ouabain or G418 (a neomycin analog) as previously described (32, 33).  All 
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cotransfections were performed using a 10:1 molar ratio of the plasmid of interest to the 
plasmid encoding the selectable marker.  The D17 cells were selected for resistance to 
puromycin (final concentration, 3.2 × 10-6 M).  The D17-derived B2-1GFFP cells were 
maintained, transfected, and selected for drug resistance in a similar manner.  PG13 cells 
(obtained from American Type Culture Collection) express MLV gag-pol and gibbon ape 
leukemia virus env (41).  D17, D17-derived, and PG13 cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 6% (D17) or 10% 
(PG13) bovine calf serum, penicillin (50 U/ml), and streptomycin (50 mg/ml).   
 Hydroxyurea (HU) treatment was performed as previously described (34).  
Briefly, D17 cells were placed on culture media containing 1 mM HU 4 h prior to 
infection, 4 h during infection, and 24 h post-infection. 
Protocol for determining the efficiency of RT template switching in vivo.  B2-
1GFFP cells were plated at a density of 2 × 105 cells per 60-mm diameter dish, and 24 h 
later were cotransfected with wild-type or mutated pLGPS and pSVα3.6.  The transfected 
cells were selected for resistance to ouabain and the resistant colonies were pooled and 
expanded.  After transfection with the pLGPS constructs, the B2-1GFFP cells were 
maintained in the presence of 1 µM 3′-azido-3′-deoxythymidine (AZT) to reduce the 
probability of reinfection of the virus-producing cells.  This concentration of AZT was 
previously shown to inhibit MLV replication 100-fold (33).  Before collecting virus, the 
culture media containing AZT was removed and the cells were plated a density of 5 × 106 
cells per 100-mm diameter dish.  The culture media was replaced with fresh media 24 h 
later.  Another 24 h later, the culture media containing ES-GFFP virus was harvested and 
used to infect D17 target cells.   
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The infected D17 cells that were resistant to G418 were pooled and analyzed by 
fluorescence-activated cell scanning (FACS).   
Southern blot analysis of proviral DNA.  Genomic DNA was isolated from the 
B2-1GFFP cell line, and the proviral DNA structure was analyzed by Southern blot 
hybridization using standard procedures (13, 51).   A 1.3-kb HindIII fragment of pVP212 
(47) containing neo was used to generate a probe (specific activity, 4.8 × 109 cpm/µg) as 
previously described (13). 
RESULTS 
Construction of B2-1GFFP cells.  The MLV-based retroviral vector pES-GFFP 
and the MLV env expression construct pSV-A-MLV-env (Fig. 1A) were introduced into 
D17 cells to generate the B2-1GFFP cells (Fig. 1B).  The vector pES-GFFP contained all 
cis-acting elements needed for viral replication, which included the LTRs, the MLV 
encapsidation signal (Ψ), the primer-binding site, and the polypurine tract.  In addition, 
the vector encoded overlapping GF and FP fragments of GFP separated by 25 bp.  The 
directly repeated sequence (the “F” portion) was 250 bp in length.  During reverse 
transcription, the directly repeated sequence was deleted at a high frequency, resulting in 
the reconstitution of a functional GFP gene (Fig. 1A).  Plasmid pES-GFFP also contained 
the selectable marker neo.  The GFFP and neo were expressed from a single RNA 
transcript initiating in the 5′ LTR.  An internal ribosomal entry site (IRES) of 
encephalomyocarditis virus was used to translate neo (27, 28, 31).   
To construct the B2-1GFFP cell line, the pSV-A-MLV-env was cotransfected 
with pBSpac into D17 cells.  The transfected cells were selected for resistance to 
puromycin and 10 cell clones were isolated and expanded.  To verify that the cell clones 
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expressed a functional amphotropic MLV envelope, the cell clones were cotransfected 
with the construct pLGPS that expressed the MLV gag-pol as well as the retroviral vector 
pGA-1 that encoded neo (Fig. 1A) (20).  G418 resistant cells were selected and virus 
produced from these cells was used to infect fresh D17 cells.  The infected D17 cells 
were selected for resistance to G418 to determine virus titers.  The B2 cell clone 
expressing amphotropic MLV envelope was selected because it exhibited the highest 
viral titer (105 CFU/ml). 
To introduce the pES-GFFP vector into B2 cells, pES-GFFP was first transfected 
into the MLV-based packaging cell line PG13, and G418-resistant cells were selected.  
Virus harvested from the pool of transfected PG13 cells was used to infect B2 cells.  
After selection for G418 resistance, five individual B2 cell clones were isolated and 
expanded.  To select a clone with undeleted directly repeated F portions of GFP, all five 
clones were analyzed by FACS.  Analyses of four of the five clones indicated that less 
than 0.4% of the cells were fluorescent.  The proportion of the cells that were fluorescent 
was similar to the proportion of fluorescent cells in uninfected D17 cells (0.1%).  FACS 
analysis of one of the clones, named B2-1, is shown in Fig. 1C (upper panel).  The 
similarity in fluorescence compared to uninfected cells indicated that the ES-GFFP 
provirus did not undergo direct repeat deletion during infection of the B2 cells.  To verify 
that the ES-GFFP provirus was capable of completing one cycle of retroviral replication, 
cell clones with undeleted direct repeats were cotransfected with pLGPS and pSVα3.6.  
Ouabain-resistant cells were selected and virus produced was used to infect fresh D17 
cells, which were selected for resistance to G418 and analyzed by FACS.  The B2-1 cell 
clone that exhibited the highest titer (105 CFU/ml) was named B2-1GFFP and used in all 
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subsequent experiments (data not shown).  Representative FACS analysis of D17 target 
cells infected with virus collected from the B2-1GFFP cells transfected with pLGPS and 
selected for G418 resistance is shown in Fig. 1C (lower panel).  A total of 11 experiments 
that were subsequently performed with the wild-type RT (Table 1) indicated that the 
deletion frequency was highly reproducible (10.4% ± 0.4%).  The presence of a high 
proportion of fluorescent cells indicated that the B2-1GFFP cells contained a functional 
ES-GFFP provirus, which was capable of undergoing direct repeat deletion during 
reverse transcription.  Control experiments performed with virus producing cells that 
were maintained in the absence and presence of AZT to reduce the probability of 
reinfection of the virus producer cells.  The experiments indicated that maintaining the 
virus producing cells in the presence of AZT did not influence the frequency of direct 
repeat deletion and GFP reconstitution (data not shown). 
It was also important to show that the B2-1GFFP cells did not express a 
replication-competent MLV, the presence of which could potentially result in multiple 
rounds of ES-GFFP replication.  ES-GFFP virus collected from the B2-1GFFP cells 
transfected with pLGPS was used to infect D17 cells.  After G418 selection, resistant 
colonies were pooled.  Culture supernatant from a pool of infected D17 cells was used to 
infect fresh D17 cells, which were then selected for resistance to G418.  The absence of 
G418 resistant colonies indicated that the B2-1GFFP cell line did not harbor a replication 
competent virus (data not shown).    
To ensure that the B2-1GFFP cells contained only one ES-GFFP provirus, 
genomic DNA was extracted from the B2-1GFFP cells and analyzed by Southern blot 
hybridization (Fig. 2).  The DNA was digested with either BamHI or EcoRI  and 
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hybridized  to a neo-specific probe.  Each of the enzymes (BamHI  and EcoRI)  cut only 
once in the ES-GFFP provirus, generating one fragment representing the 3′ portions of 
the provirus and flanking regions.  The presence of only a single detectable fragment for 
each digestion indicated that only one provirus was present in the B2-1GFFP cell line. 
Direct repeat deletion assay.  The MLV RT expression construct pLGPS was 
subjected to site-directed mutagenesis, and the B2-1GFFP cells were used to identify the 
protein determinants that were important for template switching during reverse 
transcription (Fig. 1A and B).  First, pLGPS-derived constructs containing mutations in 
the MLV RT were separately introduced into the B2-1GFFP cells by cotransfection with 
pSVα3.6.  Ouabain-resistant colonies were pooled and expanded.  Virus was harvested 
from the pools of transfected cells and serially diluted virus was used to infect D17 target 
cells.  The infected D17 cells were selected for resistance to G418 and the resulting 
colonies were pooled and analyzed by FACS to determine the frequency of direct repeat 
deletion.  In most experiments, approximately 100 to 1,000 colonies were pooled for each 
analysis.  In general, the multiplicity of infection was < 0.0005, and the probability of 
double infection was very low (<1/2000 colonies).  The frequency of direct repeat 
deletion provided a measure of the template-switching events during one cycle of 
retroviral replication.  Using this assay, the effect of mutations introduced in the MLV 
RT on template switching during reverse transcription was determined. 
All mutants that were tested in the direct repeat deletion assay are summarized in 
Fig. 3A.  Two criteria were used for selection of the RT mutants for analysis of their 
effect on template switching.  First, mutations that were previously reported to be 
important for the processivity or fidelity of reverse transcription were selected for the 
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study.  Second, only mutants that were previously shown to generate detectable viral 
titers were selected because the in vivo direct repeat deletion assay required that the 
mutants complete one cycle of retroviral replication.     
Effect of dNTP binding site and YXDD motif mutants on template switching.  
The amino acid residues of MLV RT involved in binding to the dNTP substrate were 
previously identified on the basis of sequence alignments and comparison of crystal 
structures of MLV and HIV-1 RTs (17, 21, 23, 25).  Residues L151, F155, and F156 of 
MLV RT are homologous to residues V111, Y115, and F116 of HIV-1 RT, respectively 
(Fig. 3B).   The effects of L151F, F155Y, F156W, and Q190M mutations on template 
switching were determined.  The F155Y, F156W, and Q190M mutants exhibited an 
increase in the frequency of direct repeat deletions, which ranged from 14.6% to 49.5% 
(Table 1, Fig. 4A).  However, the L151F mutation did not affect the ability of the RT to 
switch templates.  The most significant change was displayed by the F156W mutant, 
which increased direct repeat deletion frequency 4.8-fold (P < 0.00005; all statistical 
analysis was performed using the two-sample t test). 
Position V223 of the highly conserved YXDD motif of MLV RT was selected for 
mutagenesis because previous studies indicated that this amino acid was important for the 
processivity and the fidelity of RT (9, 20, 22, 53).  The results obtained from analysis of 
the V223I and V223M mutants are summarized in Table 1 and Fig. 4A.  The V223I 
mutant of MLV RT exhibited a 2-fold increase in the frequency of GFP reconstitution (P 
< 0.00005).  However, the V223M mutant of MLV RT did not exhibit a statistically 
significant alteration in the frequency of GFP reconstitution (P  = 0.246).  Therefore, 
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substitution of the V223 of MLV RT with the equivalent methionine residue in HIV-1 RT 
did not change the frequency of template switching by MLV RT (Table 1, Fig. 4A).   
Effect of thumb domain mutants on template switching.  The thumb domain of 
MLV RT was chosen as a target of mutational analysis because the HIV-1 RT crystal 
structure and in vitro assays strongly suggested that it was important for processivity (2, 
3, 5).  Since the thumb domain of the MLV RT has not yet been crystallized and there is 
no significant primary sequence homology in this region of MLV and HIV-1 RTs, the 
precise location of the MLV RT α-helix H of the thumb domain was unclear.  The 
sequence of the MLV RT and spleen necrosis virus (SNV) RT, which is similar in 
primary sequence to the MLV RT, was compared to localize the MLV RT α-helix H of 
the thumb domain.  Amino acid sequences that have maximum homology between MLV 
and SNV RTs, and are flanked by proline residues, were proposed to form an analog of 
the α-helix H of the HIV-1 RT (Fig. 3C).  Additionally, molecular modeling of the MLV 
RT thumb domain strongly suggests that this region is structurally equivalent to the α-
helix H of the HIV-1 RT (58).   
The thumb domain of MLV RT contains residues G305 and F309, which are 
hypothesized to be equivalent to the HIV-1 residues G262 and W266.  This hypothesis 
predicts that residues R301, G305, and F309 face the same side of the α-helix H and are 
involved in making contacts with the template-primer complex.  Previously, several 
mutations were introduced at all three of these residues and their effect on the fidelity of 
reverse transcription was determined (58).  For this study, the R301L, R301Q, R301S, 
F309A, F309H, and F309W mutants were selected for further analysis.  None of the 
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mutations at G305 could be tested, because mutations at this position resulted in 
undetectable viral titers (58).   
The effects of mutations at residues R301 and F309 on the frequency of direct 
repeat deletion are summarized in Table 1 and Fig. 4B.  The R301L and F309A mutants 
exhibited statistically significant reductions of 6.6% and 5.9%, respectively, in the 
frequency of GFP reconstitution (P < 0.003).  These mutants exhibited a deletion 
frequency that was 60% of the wild-type RT frequency (0.6-fold).   Conversely, the 
F309H mutant exhibited a statistically significant increase in the frequency of direct 
repeat deletions to 180% of wild type (1.8-fold, P < 0.00005).  Finally, the R301Q, 
R301S, and F309W mutants did not exhibit a statistically significant change in the 
frequency of direct repeat deletions.  Therefore, mutations of residues R301 and F309 to 
the equivalent Q and W residues found in the HIV-1 RT, respectively, did not affect the 
frequency of RT template switching. 
Effect of RNase H domain mutants on template switching.  Mutations S526A, 
Y598V, and R657S were introduced into the MLV RNase H domain, and the effects of 
these mutations on template switching were determined.  These mutations were selected 
because it was previously shown that the RNase H domain played an important role in 
obligatory template-switching events during reverse transcription (16, 54, 60, 61).  
Additionally, it was previously shown that these RNase H mutants permitted viral 
replication to occur.  These mutants exhibited much slower replication kinetics, 
suggesting that there was a defect in RNase H activity (6, 7).    
The effect of the S526A, Y598V, and R657S mutations on the frequency of direct 
repeat deletion are summarized in Table 1 and Fig. 4C.  All three RNase H mutants 
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exhibited a statistically significant reduction in the frequency of direct repeat deletions (P  
< 0.00005).  The frequency of deletions was reduced to approximately 50% of that 
observed for wild-type RT (0.5-fold).   
Effect of hydroxyurea (HU) treatment on the frequency of direct repeat 
deletion.  HU treatment has been shown to deplete all four cellular nucleotide pools and 
increase retroviral mutation rates (34).  It has been recently shown that HU treatment of 
infected cells resulted in a significant reduction in the rate of polymerization with which 
reverse transcriptions proceeds (48).   
We hypothesize that mutations in the dNTP binding site and the YXDD motif 
result in polymerases that catalyze DNA synthesis more slowly than wild-type RT, and 
that this reduction in the rate of DNA synthesis increases the frequency of RT template 
switching.  A model to explain the rationale behind this hypothesis is outlined in Fig. 6 
and discussed later.  To test this hypothesis, D17 target cells were infected with virus 
generated with the wild-type RT as well as V223I and Y598V mutants of RT in the 
absence or presence of 1 mM HU.  The frequency of direct repeat deletion and GFP 
reconstitution was determined.  The results are shown in Fig. 5 and Table 2.  In the 
presence of HU, the frequency of GFP reconstitution was increased by 1.7-fold for wild-
type RT, which was in agreement with previously published results (P < 0.0065) (48).  
Similarly, the frequency of GFP reconstitution increased 1.8-fold for the V223I mutant in 
the presence of HU (P < 0.0018), indicating that HU treatment could further increase the 
frequency of direct repeat deletion for mutants that exhibited a higher deletion frequency 
in the absence of HU.  However, HU treatment did not increase the frequency of direct 
repeat deletions for the Y598V RNase H mutant of MLV RT (P = 0.836). 
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DISCUSSION 
 A rapid and quantitative in vivo assay for RT template switching.  The 
experiments described here demonstrate that we have developed a powerful in vivo assay 
to identify structural determinants of MLV RT that are important for template switching.  
This assay is more rapid than previously described assays utilizing the herpes simplex 
virus thymidine kinase or the β-galactosidase gene because it is not necessary to compare 
viral titers after different drug selections or count numerous colonies (13, 48).  
Furthermore, the FACS analysis of infected cells allows accurate and rapid quantitation 
of the frequency of direct repeat deletion from large pools of infected cell colonies.  
However, one restriction of the assay is that it is not possible to determine the rate of 
template switching for mutants that are unable to complete one cycle of retroviral 
replication.  Nevertheless, the assay makes it possible to rapidly analyze a large number 
of RT mutants and to determine whether the structural alterations affect the frequency of 
template switching during in vivo retroviral replication. 
 Structural determinants of RT that are important for template switching.  
Our results demonstrate that several different domains of MLV  RT can affect the 
frequency of template switching.  Mutations in the dNTP binding site, the YXDD motif, 
the α-helix H of the thumb domain, and the RNase H domain can affect the frequency of 
template switching.  These results are not surprising, since previous studies have shown 
that mutations in these domains can affect RT processivity (1-3, 5, 9, 22, 30, 52, 53, 59, 
62).  It was interesting to note that most of the mutations in the YXDD motif and the 
dNTP binding site increased the frequency of RT template switching.   These mutations 
would be expected to interfere with the rate of DNA polymerization, although this effect 
 50 
has not been directly shown.  This expectation is supported by the observation that most 
of these mutants displayed lower RT activities (21).  The F156W mutant, which exhibited 
the largest increase in the frequency of RT template switching (4.8-fold), also exhibited 
the most severe defects in viral replication (2% of the wild-type titer) and RT activity 
(11% of the wild-type activity) (21).  However, the frequency of RT template switching 
was not correlated to the reduction in viral titers for other mutants, perhaps because other 
steps in retroviral replication, such as initiation of DNA synthesis, were also affected by 
these mutations.   
 Previous studies have shown that alanine-scanning mutations in the α-helix H of 
the thumb domain of HIV-1 RT greatly decreased in vitro fidelity and increased the rate 
of frameshift mutations (4, 5).  These results suggested that mutations in the α-helix H 
would decrease processivity and increase the frequency of RT template switching.  It was 
therefore surprising that most of the mutations tested in the present study either had no 
effect or decreased the frequency of RT template switching.  The only exception was the 
F309H mutant, which increased the frequency of template switching by nearly 2-fold.  It 
was especially surprising that the F309A mutant of MLV RT did not increase the 
frequency of template switching in vivo.  In vitro studies and biochemical analysis of the 
equivalent mutant in HIV-1 RT (W266A) has shown that this mutant has a very low 
affinity for the template-primer and the dissociation constant is nearly 430-fold higher 
than that observed for the wild-type HIV-1 RT (4).  The F309A mutation in MLV RT 
might affect other properties of the enzyme that prevent template switching despite its 
low template affinity.  Mutations in the primer grip have been previously shown to 
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reduce RNase H activity (18, 43).  Therefore, it is possible that the F309A mutation in 
MLV RT also affects RNase H activity, which might suppress template switching. 
 All of the RNase H mutants tested exhibited lower frequencies of RT template 
switching.  These results are consistent with previous observations that RNase H is 
essential for template switching in vitro as well as for obligatory strand transfer events 
during viral replication (16, 40, 54, 60, 61).  Interestingly, the RNase H mutants of MLV 
RT reduced the frequency of template switching by approximately 50%.  We have 
previously observed that RT template-switching events occur at very similar frequencies 
during RNA-dependent and DNA-dependent DNA synthesis (8).  According to the 
previously proposed model (14), RNase H activity is necessary for template switching 
during RNA-dependent DNA synthesis.  Therefore, the MLV RT RNase H mutants may 
severely impair template switching during RNA-dependent DNA synthesis but not affect 
the frequency of template switching during DNA-dependent DNA synthesis.  If this 
interpretation is correct, then only a small fraction of the template switching events 
observed with the RNase H mutants of MLV RT occurred during minus-strand DNA 
synthesis. 
Dynamic copy-choice model for RT template switching.  We recently 
developed a model for RT template switching (14).  The model proposed that base-
pairing between newly synthesized DNA sequences 3′ to the RT with complementary 
sequences of the template increases the probability of RT switching templates.  As RT 
copies the 3′ direct repeat, RNase H degrades the RNA template 3′ to the RT.  Next, 
hydrogen bonding occurs between the newly synthesized single-stranded DNA and 
complementary sequences in the 5′ copy of the direct repeat.  The conformational 
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rearrangements that permit this hydrogen bonding are depicted as a loop in the template 
RNA in Fig. 6.  The hydrogen-bonding interactions 3′ to the RT serve to bring the 
homologous acceptor template in close proximity to the RT, subsequently leading to 
branch migration and a template switch. 
We have modified the proposed model to incorporate observations reported in this 
study (Fig. 6).  The revised model, called the dynamic copy-choice model, proposes that 
there is a steady state between the rate of DNA polymerization and the rate of template 
RNA degradation 3′ to the RT.  The steady state determines the extent of nascent DNA 
that is available for base-pairing interactions with the acceptor template.  We propose that 
this steady state can be disturbed by affecting the rate of DNA polymerization as well as 
the rate of RNA degradation.  Once the nascent DNA 3′ to the RT is available for base-
pairing interactions with the acceptor template, the NC protein promotes hydrogen 
bonding and duplex formation (65).  After the DNA duplex forms 3′ to the RT, the 
primer end of the nascent DNA is released from the donor template, which might involve 
its dissociation from the RT.  Finally, the primer end associates with the acceptor 
template, completing the template switch.  Even though the RT template-switching 
events are portrayed as intramolecular events, the same mechanistic events could also 
result in intermolecular template-switching events.  
In this study, we observed that conditions likely to reduce the rate of DNA 
polymerization increased the frequency of RT template switching.  These conditions 
include carrying out reverse transcription with HU treatment as well as RTs containing 
mutations in the dNTP binding site and the YXDD motif.  The reduction in the rate of 
DNA polymerization may permit more efficient degradation of the template RNA and/or 
 53 
provide more time for hydrogen bond formation between the nascent DNA and the 
acceptor template.  On the other hand, when RNase H mutants of RT were used, the rate 
of RNA degradation might have been reduced, resulting in impairment of base-pairing 
interactions between the nascent DNA and the acceptor template.  As a result, the 
frequency of RT template switching was reduced.   
The dynamic copy-choice model helps to integrate some of the previously 
proposed models and experimental observations associated with RT template switching.  
First, the previously proposed forced copy-choice model is consistent with the dynamic 
copy-choice model (10).  The forced copy-choice model proposed that when RT 
encounters a break in the template RNA, the RT switches templates.  In the dynamic 
copy-choice model, a break in the RNA would represent one extreme situation in the 
spectrum in which the rate of DNA polymerization has been reduced to zero.  The 
obligatory template switches during reverse transcription, namely minus-strand and plus-
strand DNA transfer, also represent the same situation in which the rate of DNA 
polymerization is zero.  Second, the dynamic copy-choice model is consistent with 
several previous observations that secondary structures in the template RNA create RT 
pause sites, increasing the frequency of template switching (37, 38, 45, 55-57, 69).  Since 
RT pausing is likely to reduce the rate of DNA polymerization, its effect on RT template 
switching should be similar to that observed for HU treatment or RT mutants expected to 
reduce the rate of DNA polymerization. 
Our observation that HU treatment did not increase the frequency of RT template 
switching for the RNase H mutant Y598V suggests that decreasing the rate of DNA 
polymerization is unable to overcome this particular defect in RNase H activity.  
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Although at first glance this observation appears surprising with respect to the dynamic 
copy-choice model, the interpretation of the result is dependent on the extent to which the 
template-switching events observed with the Y598V mutant of MLV RT occurred during 
minus-strand DNA synthesis.  The observation that HU treatment did increase the 
frequency of template switching for wild-type RT suggests that the rates of DNA 
polymerization and RNase H degradation are similar.  It is possible that the RNase H 
activity of the Y598V mutant of RT is substantially lower than the wild-type RNase H 
activity.  If so, the HU treatment might not be able to compensate for this substantial 
RNase H defect by reducing the rate of DNA polymerization.  As discussed earlier, only 
a small fraction of the template-switching events observed with this mutant may have 
occurred during minus-strand DNA synthesis.  For example, if we assume that 25% of 
the template switching events observed with the Y598V mutant of MLV RT occurred 
during minus-strand DNA synthesis, then only 1% of the proviruses underwent direct 
repeat deletion during minus-strand DNA synthesis (25% of an overall deletion 
frequency of 4%).  If the frequency of direct repeat deletion during minus-strand DNA 
synthesis is increased by approximately 2-fold with HU treatment, then the overall rate of 
direct repeat deletion would be expected to increase from 4% to 5%.  The direct repeat 
deletion assay used in this study may not be sufficiently sensitive to detect such a small 
increase in the deletion frequency.  
It is also important to note that the size of the direct repeats might determine the 
sensitivity of the assay and whether a defect in RNase H activity can be overcome to a 
level that can be detected by reducing the rate of polymerization.  It is possible that 
increasing the size of direct repeat will increase the time frame in which a defective 
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RNase H can degrade the template RNA.  Consequently, the frequency of RT template 
switching events that occur during minus-strand DNA synthesis will be increased for all 
RTs.  Since the overall frequencies of direct repeat deletions will be higher, the overall 
sensitivity of the assay should be increased. 
It must be pointed out that the Y598V mutant of RT was previously shown to 
have 100% polymerization-independent RNase H activity in an in vitro assay (7).  
However, it is unknown whether the polymerization dependent and/or the 
polymerization-independent activities of RNase H are important for RT template 
switching.  Furthermore, it is unclear whether the in vitro RNase H activity reflects the 
level of activity that is displayed in the context of in vivo viral replication.  The Y598V 
mutant of RT most likely has a defect in RNase H activity in vivo, since it exhibited 
slower kinetics of viral replication and a 5-fold reduction in viral titer (6, 20).  Therefore, 
it is possible that the Y598V RNase H defect cannot be overcome by decreasing the rate 
of DNA polymerization with HU treatment.   
Finally, other structural determinants of RT as well as other viral proteins not 
analyzed in this study might have a strong influence on RT template switching. 
Specifically, the NC protein has been shown to promote minus-strand and plus-strand 
DNA transfer events, and might play an important role in stabilizing the hydrogen 
bonding between the nascent DNA and acceptor template (19, 68).  Experiments to 
analyze the role of other structural determinants of RT and NC in template switching are 
underway. 
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TABLE 1.  Effect of mutations in MLV RT on the frequency of direct repeat 
deletion and GFP reconstitution  
               
MLV RT 
mutants 
 
No. of 
experiments 
 
Total no. of 
coloniesa  
Frequency of 
direct repeat 
deletions  
(mean % ± SE)b 
Relative change 
in direct repeat 
deletion 
frequencyc 
Wild type 11 7333 10.2 ± 0.4 1.0 
             
     dNTP binding site      
L151F 3  530   9.2 ± 0.1 No change 
F155Y 2  336      14.6 ± 2.6 1.4 
F156W 6  544 49.5 ± 5.4 4.8 
Q190M 3  444 18.4 ± 2.1 1.8 
     
      YXDD motif     
V223I 6 1597 20.2 ± 1.0 2.0 
V223M 3  297   9.2 ± 0.1 No change 
     
     Thumb domain      
R301L 3  418   6.6 ± 1.2 0.6 
R301Q 2  601   7.7 ± 0.1 No change 
R301S 2  517   9.2 ± 1.6 No change 
F309A 6  408   5.9 ± 0.7 0.6 
F309H 2  265 18.0 ± 1.0 1.8 
F309W 3  832 11.9 ± 2.0 No change 
     
     RNase H domain      
S526A 6 2047   5.3 ± 0.3 0.5 
Y598V 12 5120   5.0 ± 0.4 0.5 
R657S 6 2099   5.3 ± 0.5 0.5 
a Total number of colonies analyzed by FACS in 2 to 12 independent infections.   
b Frequency of direct repeat deletion was determined as a percent of infected D17 
target cells that exhibited fluorescence after G418 selection compared to the negative 
control.  The standard error of the mean (SE) was determined by using the Sigma Plot 5.0 
program.  
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c Calculated as follows: frequency of direct repeat deletion observed with mutant 
MLV RT ÷ frequency of direct repeat deletion observed with the wild-type RT.   
Statistically significant changes in the frequency of direct repeat deletions, relative to the 
wild-type RT (set to 1.0) are shown (two-sample t test: P < 0.05).   
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TABLE 2.  Effect of HU treatment on the frequency of direct repeat deletion and 
GFP reconstitution  
               
MLV RT 
 
No. of 
experiments 
 
Total no. of 
coloniesa  
Frequency of 
direct repeat 
deletions  
(mean % ± SE)b 
Relative change 
in direct repeat 
deletion 
frequencyc 
WT 5 4392       9.9 ± 0.7 1.0 
WT + HU 6   632 17.2 ± 1. 8 1.7 
     
V233I 3   755 18.0 ± 1.3 1.0 
V233I + HU 3   212 32.7 ± 1.5 1.8 
     
Y598V 3 1059   4.0 ± 0.3 1.0 
Y598V + HU 3   450   3.9 ± 0.8 1.0 
 
a Total number of colonies that were analyzed by FACS in 3 to 6 independent 
infections.   
b Determined as for Table 1. 
c Calculated as follows: frequency of direct repeat deletion observed with mutant or wild-
type MLV RT ÷ frequency of direct repeat deletion observed with the same MLV RT in 
the presence of 1 mM HU.  Statistical analysis using the two-sample t test showed that 
the wild-type as well as the V233I mutant of MLV RT displayed direct repeat deletion 
frequencies different from that observed in the presence of 1 mM HU (P < 0.01).  The 
direct repeat deletion frequencies obtained with the Y598V mutant of MLV RT were not 
significantly different in the presence or absence of HU (P = 0.836). 
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FIGURE LEGENDS AND FIGURES 
FIG. 1.   Structures of MLV-based constructs and direct repeat deletion 
assay to identify structural determinants of MLV RT important for template 
switching.  (A) Structures of MLV-based vector pES-GFFP, pLGPS, and pSV-A-MLV-
env.  The pES-GFFP vector contains LTRs and all cis-acting elements of MLV.  The 
GFFP and neo are transcribed from the LTR promoter.  IRES of encephalomyocardidtis 
virus is used to express neo.  The directly repeated F portion of GFP is shaded and 
indicated by overhead arrows.  During reverse transcription, the repeated F portion may 
be deleted to reconstitute a functional GFP.  The pLGPS construct expresses the MLV 
gag and pol from a truncated viral LTR.  The pSV-A-MLV-env construct expresses the 
amphotropic MLV envelope from a truncated MLV LTR and the SV40 promoter 
enhancer. Ψ, MLV packaging signal.  (B) Experimental protocol.  B2-1GFFP, a D17-
based cell line expressing pES-GFFP and pSV-A-MLV-env, was constructed.  The wild-
type or mutated pLGPS constructs were separately cotransfected (Tf) with pSVα3.6 into 
the B2-1GFFP cells and the virus produced was used to infect (Inf) D17 cells.  The 
infected cell clones resistant to G418 were analyzed by FACS and frequencies of direct 
repeat deletion were determined. (C) Top panel shows FACS analysis of B2-1GFFP 
cells.  Bottom panel shows FACS analysis of D17 target cells infected with virus 
collected from the B2-1GFFP cells transfected with wild-type pLGPS and selected for 
G418 resistance.  
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FIG. 2.  Southern analysis of B2-1GFFP cells.  Structure of ES-GFFP provirus 
is shown.  Thick zig-zag lines represent host cell DNA flanking the provirus.  The 
approximate locations of a BamHI and an EcoRI restriction site in the provirus, and the 
expected lengths of the restriction fragments are shown.  Genomic DNA isolated from 
B2-1GFFP cells was digested with either EcoRI (lane E) or BamHI (lane B).  The blot 
was hybridized to a neo-specific probe (black bar). 
FIG. 3.  Mutants of MLV RT.  (A) Selected regions of the MLV RT primary 
sequence containing the dNTP binding site, the YXDD motif, the α-helix H of the thumb 
domain, and the RNase H are shown and labeled.  The numbers above the primary 
sequence indicate the amino acid positions in the primary sequence.  The substitution 
mutations analyzed at each amino acid position are indicated below the primary sequence 
with downward arrows.  (B) Primary sequence alignment of the MLV RT and HIV-1 RT 
dNTP binding sites.  Double dots represent identical amino acids, whereas single dots 
represent conserved amino acids.  The numbers indicate amino acid positions in the 
primary sequence.  (C) Primary sequence alignment of the α-helix H of the HIV-1 RT 
thumb domain and corresponding sequences in MLV and SNV RTs. 
FIG. 4.  Effect of mutations in the MLV RT dNTP binding site and YXDD 
motif (A), the α-helix H of the thumb domain (B), and the RNase H domain (C) on 
the frequency of GFP reconstitution.   The frequencies of GFP reconstitution were 
determined by FACS analysis and are shown for wild-type RT (open bars) and mutant 
RTs (shaded bars).  The results represent and average of 2 to 12 experiments, and the 
error bars represent the standard error of the mean. 
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  FIG. 5.  Effect of HU treatment on the frequencies of GFP reconstitution 
exhibited by the wild-type, V223I mutant, and Y598V mutant of MLV RT.  The 
open and shaded bars represent the frequencies of GFP reconstitution observed in the 
absence and presence of HU treatment, respectively.  The results represent an average of 
3 to 6 experiments, and the error bars represent the standard error of the mean. 
FIG. 6.  Dynamic copy-choice model for RT template switching.  Shaded 
boxes represent direct repeats in an RNA template.  Horizontal arrows represent nascent 
DNA.  The thickness of these arrows indicate the relative polymerization rate: the thicker 
the arrow, the faster the rate of polymerization.  Small open boxes represent degraded 
RNA by the RNase H domain. In the case of slow RNase H activity, the degraded RNA 
fragments are shown as larger open boxes.  Hydrogen bonds between the RNA template 
and nascent DNA are designated by vertical marks.  Vertical arrows of various thickness 
indicate the relative efficiency of template switching.   
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 ABSTRACT 
 Structural determinants of retroviral reverse transcriptases (RTs) that are 
important for in vivo fidelity are currently being elucidated.  We sought to 
determine whether a minor groove binding helix of the thumb domain and primer 
grip of murine leukemia virus (MLV) RT are important for in vivo fidelity of 
reverse transcription.  Because the thumb domain of MLV RT has not been 
crystallized, we utilized homology alignment and molecular modeling to identify 
residues 297-311 as the MLV RT equivalent of human immunodeficiency virus type-
1 (HIV-1) minor groove binding helix (α-helix H).  Substitution mutations of several 
residues of the MLV RT minor groove binding helix and the primer grip were 
generated and their effects on viral replication, RT activity and in vivo fidelity of 
reverse transcription were determined.  We employed a previously described in vivo 
fidelity assay, which measured the frequency of inactivation of bacterial β-
galactosidase gene in a single cycle of retroviral replication.  Mutations in the minor 
groove binding helix residues R301 and F309 decreased the RT fidelity by up to 2.8-
fold.  Mutations of residues G305 and W313 resulted in > 10,000-fold reductions in 
viral titer indicating that these residues are essential for viral replication.  Extensive 
mutational analysis of the MLV RT primer grip residue L269 indicated that 7 of 8 
substitutions resulted in >10,000-fold reductions in viral titer; the L269T mutant 
replicated but did not display any alterations in fidelity of reverse transcription.  
These results identify the minor groove binding helix of the thumb domain of MLV 
RT and indicate that it is important for accuracy of viral DNA synthesis.   
 81 
INTRODUCTION 
 High evolutionary potential and genetic variation in retroviral populations 
increases the fitness of the retroviral species.  In case of human immunodeficiency virus 
type-1 (HIV-1), high genetic variation has resulted in the selection of viral variants 
containing mutations that confer resistance in vivo and in tissue culture experiments to at 
least 116 antiretroviral drugs (52).  The genetic variation in retroviral populations is 
generated by their high rates of mutations and recombination (9, 23, 24, 36, 37, 43-45, 
48, 49, 56).  The majority of retroviral mutations are introduced into the viral genome by 
error-prone reverse transcriptase (RT), a virally encoded enzyme that converts single-
stranded viral RNA into double-stranded DNA.  The low fidelity of reverse transcription 
has been well documented by studying mutation rates of RTs in vivo and in vitro (36, 37, 
43-45, 48, 49).   Two properties of RT are likely to be responsible for the low fidelity of 
DNA synthesis during reverse transcription.  First, RT lacks a proofreading activity that 
is present in most cellular polymerases.  Second, it has been hypothesized that because 
two template-switching events are necessary for the completion of reverse transcription, 
retroviral RTs have evolved to possess low template affinity and low processivity (56).  
Low template affinity and low processivity may cause additional intramolecular and/or 
intermolecular template switching events resulting in deletions and recombination.   
The structure of RT is likely to play an important role in its low template affinity 
and low processivity.  Several crystal structures of HIV-1 RT have been reported, 
including co-crystals with non-nucleoside inhibitors, DNA, and a ternary complex with 
bound DNA and a substrate dTTP (10, 25, 33, 53).  HIV-1 RT is a heterodimer composed 
of p66 and p51 subunits.  The p66 subunit resembles a right hand and possesses a 
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polymerase and an RNase H activity.  The domains of p66 subunit are referred to as 
fingers, palm, thumb, connection, and RNase H.  The p51 subunit lacks the RNase H 
domain and folds in a different conformation.  The murine leukemia virus (MLV) RT is a 
monomer in solution and may form a homodimer consisting of two p75 subunits upon 
interaction with a template-primer (55).  A partial MLV RT crystal structure has been 
solved for an N-terminal segment of the protein containing the fingers and the palm 
domains (14, 41).  Despite a low primary sequence homology between HIV-1 and MLV 
RTs, the three dimensional structures of these proteins are very similar (14). 
Several in vitro and in vivo studies have implicated structural determinants of RT 
that may be important for its fidelity (1, 11, 12, 17-20, 31, 38, 39, 51, 57).  These 
structural determinants include residues of the Tyr-X-Asp-Asp (YXDD) motif (1, 18, 57), 
the deoxyribonucleotide triphosphate (dNTP)-binding site (12, 19, 20, 38, 39, 51), RNase 
H domain (18) as well as E89 (11), D76 (31), and F160 (17) in HIV-1 RT.   
The thumb domain and the primer grip region are involved in the positioning of 
the template-primer complex and the affinity of RT to the template-primer.  Therefore, 
these regions may also play an important role in RT fidelity.  In the HIV-1 RT, the thumb 
domain is composed of a bundle of α-helices and refers to residues 244-322 (33).  It has 
been proposed that the α-helix H and α-helix I form a “helix clamp” and maintain 
contacts with the template-primer complex during the translocation step of 
polymerization (21, 22).  The α-helix H of HIV-1 RT is positioned in the minor groove 
of the template-primer complex (10).  Several residues of the α-helix H are part of the 
motif named as the minor groove binding tract (Q258, G262, W266, Q269, and I94) 
which makes DNA sequence independent contacts two to six base pairs upstream of the 
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3′ end of the primer (6, 25).  Alanine-scanning mutagenesis of the α-helix H and α-helix 
I showed that mutations within the α-helix H but not α-helix I displayed lower affinity 
for the template-primer, lower processivity, and frameshift fidelity (2-6).  Mutations at 
the G262 and W266 residues exhibited the most effect on the binding affinity for the 
template-primer complex, processivity, and fidelity of HIV-1 RT.  Additionally, it has 
been shown that mutations in the thumb domain, especially at the G262 and W266, 
significantly reduce the amount of full-length DNA product generated, efficiency and 
specificity of RNase H activity, and efficiency of the strand transfer reaction (13).  
Another recent study indicated that substitutions at the α-helix H and α-helix I residues 
result in a loss of cleavage specificity with PPT-containing substrates (46).    
The primer grip region is composed a hairpin of two antiparallel β-sheets of the 
palm subdomain and consists of highly conserved residues 224-235 (25, 26).  It has been 
postulated that the main function of the primer grip is to position the 3′-OH of the primer 
near to the active site of RT.  Several studies have indicated that mutations at the primer 
grip could affect the binding affinity of RT to the primer and the efficiency with which 
the RNA primer is extended during minus-strand DNA synthesis (15, 16, 27, 42, 47, 59).  
In addition, the primer grip residues are involved in the proper positioning of RT for 
processing and extension of the polypurine tract (PPT) (47).  Recent in vitro data showed 
that mutations of amino acids at different positions in the primer grip could also affect the 
misincorporation fidelity of HIV-1 RT (58).  Interestingly, some of the mutants were able 
to improve in vitro RT fidelity.  It was hypothesized that the wild type RT has evolved to 
possess suboptimal fidelity to allow generation of genetic variation (58).  
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In this study, we identified a region of MLV RT that is analogous to the minor 
groove binding helix (α-helix H) of HIV-1 RT.  We performed mutational analysis of the 
minor groove binding helix and primer grip residues to elucidate the role of these regions 
in fidelity of MLV RT during reverse transcription in vivo.  The result showed that 
proper interactions of RT with primer-template complex are very important for retroviral 
replication and may affect in vivo fidelity.   
MATERIALS AND METHODS 
Plasmids.   Plasmid pLGPS expressed the MLV gag and pol genes from a 
truncated MLV long terminal repeat (LTR) promoter (40).  The plasmid pSV-A-MLV-
env, which expressed the amphotropic MLV envelope gene from the LTR promoter and 
SV40 enhancer, was obtained from the AIDS Research and Reference Reagents Program 
(34).  The plasmid pSVα3.6 encoded the α subunit of the murine Na+, K+-ATPase gene 
and conferred resistance to ouabain (30).  Plasmid pGA-1, a MLV-based retroviral 
vector, encoded the neomycin phosphotransferase gene (neo) as well as the β-
galactosidase gene (lacZ) (29).  
  Generation of MLV RT mutants.  A detailed description of the mutagenic 
oligonucleotides and strategies used to generate mutants is available upon request.  Briefly, 
to simplify the mutagenesis procedure, we first constructed pES4, a plasmid analogous to 
pLGPS that contained only two BamHI sites flanking the primer grip and the minor groove 
binding helix region.  The pES4 was generated by destroying a BamHI site (6601) within 
pRMBNB, a derivative of pLGPS (19).  The destroyed BamHI site was located outside of 
the gag-pol coding region.  PCR-based mutagenesis with random mutagenic primer sets 
and pES4 as the template was utilized to generate mutants at residues L269, R301, G305, 
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F309, L312, and W313.  Mutagenic primer sets contained additional silent mutations to 
generate a restriction site for screening purposes.  Amplified DNA fragments of 306 bp 
were digested with BamHI and subcloned back into pES4.  L269 mutants were screened for 
the presence of a new KpnI site (3797).  R301 and G305 mutants were identified by 
digestion with EcoRI (new site introduced at position 3889).  F309 mutants were identified 
by digestion with PstI (new site introduced at position 3901).  L312 and W313 mutants 
were screened for the presence of a new PstI site (3928).  Finally, the mutated plasmids 
were analyzed by DNA sequencing to verify the presence of the desired mutation and the 
absence of any undesired mutations (ALF Automated Sequencer, Pharmacia). 
  Cells, transfections, and infections.  D17 dog osteosarcoma cells (obtained from 
American Type Culture Collection) were transfected, infected, and selected for resistance 
to ouabain or G418 (a neomycin analog) as previously described (28, 29).  All 
cotransfections were performed using a 10:1 molar ratio of the plasmid of interest to the 
plasmid encoding the selectable marker.  D17 and D17-derived cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 6% bovine calf serum, 
penicillin (50 U/ml), and streptomycin (50 mg/ml).   
 Virus preparation, RT assays, and Western blotting.  Virus isolation, 
concentration, RT assays, and Western blots were performed as previously described     
(18).  Briefly, helper cells containing different pLGPS constructs were plated at 5 × 106 
cells per 100-mm dish, 24 h later media was changed with fresh media containing 1% 
calf serum, and an additional 2 days later viruses were collected and centrifuged at 
25,000 rpm for 90 min in an SW41 rotor (Beckman) at 4ºC.  Viral pellets were 
resuspended in phosphate-buffered saline and virus was stored at –80º C.  
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 Exogenous RT activities were determined as previously described using 50 µg/µl 
of (20-mer) oligo (dT) (Integrated DNA Technologies), 100 µg/ml of poly (rA) 
(Pharmacia), and 10 µCi of [3H]-dTTP (specific activity of 72 Ci/mMol, ICN).  The 
amount of [3H] dTTP incorporated was determined using a scintillation counter. 
 Western blots were used to quantify the amount of protein for the RT assays and 
performed using standard procedures (50).  Briefly, viral proteins were resolved using a 
13.8% SDS-PAGE and transferred to membranes (Gelman Sciences, Inc.).  Membranes 
were incubated with primary (monoclonal anti-MLV capsid (CA) IgG1; 1:10 dilution 
[ATCC]) (8) and secondary antibodies (anti-rat IgG antibody conjugated to horseradish 
peroxidase; 1:10,000 dilution [Southern Biotechnology Associates, Inc.]).  Detection of 
MLV CA was performed using an ECL (enhanced chemiluminenesence) kit TM 
(Amersham Pharmacia Biotech).  The membranes were then exposed to X-OMAT film 
(Kodak) and the intensity of the p30 band was quantitated using the Image Quant 
program (Molecular Dynamics).  
   Protocol for in vivo fidelity assay.  The in vivo fidelity assay was described 
previously (18).  Briefly, the ANGIE P cells were plated at a density of 2 × 105 cells per 
60-mm-diameter dish, and 24 h later were cotransfected with wild type or mutated 
pLGPS and pSVα3.6.  The transfected cells were selected for resistance to ouabain (10-7 
M), resistant colonies were pooled, expanded, and plated at a density of 5 × 106 cells per 
100-mm-diameter dish.  After 48 h, the culture medium containing GA-1 virus was 
harvested and used to infect D17 target cells plated at a density of 2 × 105 cells per 60-
mm-diameter dish.  Infected D17 cells were selected for resistance to G418 (400 µg/ml) 
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and stained with 5-bromo-4-chloro-indolyl-β-D-galactopyranoside (X-Gal) as previously 
described (29).   
 Molecular modeling.  The homology modeling tools available in the program 
Look were used to model the three-dimensional structure of the 267-316 amino acids of 
the MLV RT (Look version 3.0 is an Integrated Protein Research Tool, Molecular 
application Group, Palo Alto, CA).  The coordinates of crystal structure of a covalently 
trapped catalytic complex of HIV-1 RT were employed as a structural template for 
homology model building (7, 25).   
RESULTS 
Identification of the minor groove binding helix of the MLV RT thumb 
domain.  We identified the minor groove binding helix of the MLV RT thumb domain 
through homology alignment of 40 highly divergent RT sequences (Fig. 1).  A simple 
alignment of MLV RT and HIV-1 RT did not reveal significant homology in the region 
of the α-helix H and could not be utilized to identify the minor groove binding helix of 
MLV RT.  We first aligned the primer grip, a highly conserved region among all 
retroviral RTs.   The primer grip consists of the following sequence: Y/W/F-L/M-G-X.  
The X residue is an aromatic amino acid in 30 of 40 RT sequences.  In the remaining 
RTs, the X residue is a Q (HTLV/BLV viruses and walleye epidermal hyperplasia 
viruses), L (multiple sclerosis associated virus and cauliflower mosaic virus), or T 
(mouse mammary tumor virus).  We identified a G-X-X-X-W/F/Y motif approximately 
30 amino acids downstream of the primer grip in 39 of 40 RT sequences.  The only 
exception was the avian myeloblastosis-associated virus type 1, which contains a G-X-X-
X-S sequence.   The distance between the primer grip and the G-X-X-X-W/F/Y motif 
 88 
was conserved, and varied between 28 to 33 amino acids for retroviral RTs.  This 
distance was slightly longer for nonretroviral RTs (34 and 39 amino acids for cauliflower 
mosaic virus and hepatitis B virus, respectively).  The amino acid G262 through W266 of 
HIV-1 RT α-helix H constitute the G-X-X-X-W/F/Y motif.  The sequences of the MLV 
RT that are adjacent to the G-X-X-X-W/F/Y motif are highly conserved among the C-
type retroviruses, suggesting that they form a structural determinant that is important for 
RT function.  In contrast, the sequences between the primer grip and the G-X-X-X-
W/F/Y motif are not highly conserved within each group of retroviruses, indicating that 
RTs can tolerate changes in this region without disruption of RT function.  Nevertheless, 
some amino acids between the primer grip and the G-X-X-X-W/F/Y motif appeared to be 
semiconserved in the majority of RT sequences (Fig.1, shaded residues).  For example, 
residues equivalent to the T296 of MLV RT are either a T or an S in 33 of 40 RT 
sequences.  The presence of these semiconserved residues supports the alignment of the 
G-X-X-X-W/F/Y motif.   
It has to be mentioned that MLV RT sequence contains another G at position 308 
that could be aligned with G262 of HIV-1 RT.  However, this alignment of G308 of 
MLV RT with G262 of HIV-1 RT results in positioning L312 of MLV RT in a position 
of the highly conserved aromatic residue W266 of HIV-1 RT.  On the other hand, 
alignment of the W266 of HIV-1 RT with W313 of MLV RT results in positioning F309 
of MLV RT in a position of the highly conserved G262 of HIV-1 RT.  Therefore, G308 
and W313 of MLV RT are not likely to constitute the G-X-X-X-W/F/Y motif.  
Homology modeling of the minor groove binding helix of the MLV RT 
thumb domain.  To further confirm the identification of the MLV RT minor groove 
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binding helix, we built the homology model of the MLV RT amino acids 267 to 316, 
using the crystal structure of HIV-1 RT bound to the dTTP and DNA as a template (7, 
25).  The sequence of the homology model included region starting from the primer grip 
and extended 7 amino acids beyond the G-X-X-X-W/F/Y motif.  The homology model 
was linked at the G270 residue with the crystal structure of fingers and palm domains of 
MLV RT fragment.  The connection between the two fragments was done visually on a 
computer graphics screen using the modeling program INSIGHT II (BIOSYM/MSI, San 
Diego, CA) avoiding contacts between these two fragments.  A ribbon representation of 
the superimposed structures of the fingers and palm domains of the MLV RT, modeled 
thumb domain of MLV RT over the corresponding domains of the HIV-1 RT are shown 
in Fig. 2A.  The magenta colored ribbon shows the homology model of the MLV RT 
residues 267-316, which include the predicted minor groove binding helix.  We were able 
to build energetically favorable model of the thumb domain of MLV RT using the thumb 
of HIV-1 RT as template, even though there is not much sequence homology between 
these two RTs at this region. 
The modeled region of MLV RT was four amino acids longer than the 
homologous sequence of HIV-1 RT.  Based on the HIV-1 RT structure, we positioned 
amino acid Q277 in a loop and amino acids TPK (293-295) in another loop (these loops 
are indicated by yellow colored ribbon in Fig. 2B).  The residues Q277 and TPK (293-
295) were not modeled, but are presumed to increase the size of the loop without having 
a substantial effect on the overall structure.  The gaps in the sequence alignments in Fig. 
1 reflect the view that amino acids equivalent to the MLV RT residues 277 and 293-295 
are not present in the HIV-1 RT.  
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We analyzed interactions of the identified minor groove binding helix with DNA 
primer (Fig. 2C).  It appears that the G305 and F309 of MLV RT, which constitute the G-
X-X-X-W/F/Y motif, interact with the primer strand in a manner similar to as G262 and 
W266 of HIV-1 RT.  The Cα atom of the G305 forms van der Waals contact with a sugar 
ring oxygen atom of the fourth nucleotide upstream of the 3′ end in the primer strand.  
Residue F309 makes favorable hydrophobic “stacking” interactions with the sugar atoms 
in the third nucleotide upstream of the 3′ end in the primer strand.  The R301 residue 
does not appear to form contacts with the primer strand and possibly could be exposed to 
solvent.  Additionally, we proposed that R297 and E302 of MLV RT could form salt-
bridge interactions to stabilize a helical structure of this region (Fig. 2C).  D256 and 
K259 of HIV-1 RT can potentially form similar salt-bridge interactions.  Molecular 
modeling of the MLV RT thumb domain also revealed that Y271, W279, and W313 form 
hydrophobic interactions, which might be necessary for a proper folding of the thumb 
domain.  Interestingly, these residues are conserved in C-type retroviruses.  Similar 
hydrophobic interactions are formed by Y232, W239, and I270 of HIV-1 RT. 
Mutational analysis of the thumb domain of MLV RT.  The importance of the 
identified minor groove binding helix and adjacent residues of the MLV RT for fidelity 
of reverse transcription was tested using a previously described in vivo assay (18).  
Briefly, the MLV gag-pol expression construct pLGPS was subjected to site-directed 
mutagenesis and cotransfected into the ANGIE P cells, which stably express the MLV-
based retroviral vector pGA-1 and the MLV envelope expression construct pSV-A-MLV-
env (Fig. 3A).  Virus harvested from the transfected cell pools was used to infect D17 
target cells.  The infected D17 cells were selected, stained with X-Gal, and the frequency 
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of lacZ inactivation was determined by dividing the number of white colonies by the total 
number of colonies (blue plus white colonies).  The frequency of lacZ inactivation and 
virus titers provided measures of the in vivo fidelity of reverse transcription and the 
efficiency of virus replication, respectively (Fig. 3A).   
Mutations introduced into the minor groove binding helix of the thumb domain of 
MLV RT are summarized in Fig. 3B.  We mutated amino acid residues R301, G305, and 
F309 because these residues were expected to contact the template primer and therefore 
were most likely to affect RT affinity and proper binding to the template-primer.  
Additionally, mutations at the homologous Q258, G262, and W266 positions of HIV-1 
RT displayed the greatest effect on in vitro fidelity, frequency of frameshift mutations 
and processivity (2-6).  We also performed mutational analysis on L312 and W313 
because these amino acids are positioned next to the primer grip and are facing the 
template-primer complex.   
The effects of these mutations on in vivo fidelity during reverse transcription were 
determined and compared to the fidelity of the wild-type MLV RT in parallel 
experiments (Table 1).  Utilization of the wild-type MLV RT consistently resulted in the 
inactivation of lacZ with a mean of 5.9% (Standard error, ± 0.4%).  A total of 7 
substitutions were introduced at the R301 position using vertical mutagenesis procedures.  
Most of the substitutions resulted in significant reductions of viral titers, ranging from 20- 
to greater than 10,000-fold.  The only exception was the substitution of R301 with Q, 
which displayed only a 3-fold reduction in the viral titer.  Notably, a glutamine is present 
at the equivalent position in the HIV-1 RT as well as 30 of 40 RT sequences analyzed in 
Fig. 1.  Substitution of the R301 with P, which is expected to disrupt α-helices, resulted 
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in undetectable viral titers.  Most of the substitutions resulted in statistically significant 
1.5- to 1.9-fold increases in the rates of lacZ inactivation (P < 0.05).   
All 8 substitutions at the G305 position resulted in undetectable viral titers.  This 
result was consistent with the observation that a glycine is present in all 40 of the RT 
sequences analyzed in Fig. 1 and indicated that it is very critical for RT function and 
retroviral replication.   
A total of 9 substitutions at the F309 position were analyzed.  Substitution of the 
F309 with a W, which is present at the equivalent position in HIV-1 RT and 25 of the 40 
RT sequences analyzed in Fig. 1, displayed the least reduction in viral titer.  The F309W 
displayed a small, but statistically significant increase in fidelity (0.7-fold decrease in 
frequency of lacZ inactivation, P < 0.05).  F309T and F309V did not reduce titers 
significantly and decreased the accuracy of DNA synthesis.  Similar to the R301P, the 
F309P substitution resulted in undetectable viral titers, reinforcing the view that this 
region forms an α-helix.  The rest of the mutations also displayed significant reduction in 
titers ranging from 33- to 1,000-fold.  These mutations resulted in an increase in mutation 
frequencies (1.7- to 2.8-fold).   The substitution of F309 with A, a small hydrophobic 
residue, displayed the most affect on mutant frequency, suggesting that the F309 residue 
is important for fidelity of DNA synthesis. 
Although amino acids L312 and W313 are not conserved among retroviruses, 
they are present in all C-type retroviruses.  Because most of the mutations at L312 and 
W313 resulted in significant reduction of viral titers (< 10,000-fold), it was not possible 
to determine the effect of these mutations on fidelity.  However, L312R mutant virus 
displayed some titer resulting in 82 colonies which we stained with X-Gal and the affect 
 93 
of this mutation on the frequency of lacZ inactivation was determined.  While the 
mutation resulted in a two-fold increase in mutant frequency, the number of colonies 
obtained was insufficient to achieve statistical significance.  
 DNA polymerization activities of the thumb domain MLV RT mutants.  We 
measured virus associated DNA polymerization activity for the thumb region mutants to 
determine whether this activity could account for the reduction in viral titers (Fig. 4).  
Virus was collected from the same number of virus producing cells and pelleted by 
ultracentrifugation.  To normalize the amount of virus used, an aliquot of the viral sample 
was analyzed by Western blotting using anti-MLV CA antibodies (data not shown).  The 
DNA polymerization activity of the wild type MLV RT was set to 100% and DNA 
polymerization activity of each mutant was expressed as a percentage of the wild type in 
parallel experiments.   
 The R301Q displayed the highest RT activity as well as the highest viral titer 
among the R301 mutants tested.  With the exception of R301I, the rest of the mutants at 
this position exhibited low DNA polymerization activities ranging from 8 - 23% and 
displayed viral titers that were lower than 2% of wild type.  The R301I mutant exhibited 
approximately 30% of DNA polymerization activity, but the titer of this mutant (0.5% of 
wild type) was lower than titers of the other RT mutants that exhibited lower than 30% 
DNA polymerization activities.  This suggested that R301I may possess a defect not only 
in DNA polymerization but also in other functions of RT, such as initiation of minus- or 
plus-strand synthesis or strand transfer events.  The DNA polymerization activities of 
G305 mutants were generally low, consistent with the low virus titers; however some of 
the mutants exhibited up to 40% of DNA polymerization activity (for example G305Q), 
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indicating that G305 may play a role in other RT activities mentioned above as well as 
DNA polymerization.  Similar to R301Q, the F309W mutant displayed nearly wild-type 
DNA polymerization activity.  This result was in agreement with the highest titer of 
F309W mutant among the F309 mutants.   Some of the mutants at this position (F309A, 
F309H, F309I, and F309V) exhibited RT activities higher than wild type and still 
displayed low titers.  These mutants may possess defects in RNase H activity and result 
in increased DNA synthesis.  We have previously observed that some RNase H mutants 
exhibit DNA polymerization activities that are grater than wild-type RT (18).  It is 
possible that defects in RNase H activity reduce the rate of degradation of poly rA 
template, which may account for more efficient DNA synthesis in the assay.  The DNA 
polymerization activity of the F309L mutant was nearly 70%, but the titer of this mutant 
virus was 1,000-fold lower than the wild type virus titer.  The DNA polymerization 
activities of R301P and F309P were 12% and 33%, respectively, suggesting that 
disruption of the minor groove binding helix of MLV RT thumb domain does not 
completely eliminate DNA polymerization by the mutant RT.  L312E and L312R 
mutants displayed approximately 40% and 70% of wild-type DNA polymerization 
activity, but possessed very low titers.  Low titers of W313 may be explained by a 
deficiency in other DNA polymerization activities of these mutants.  Overall, the DNA 
polymerization activity data indicates that not all reduction in titers of viruses containing 
a mutation in the thumb region of MLV RT are due to reductions of DNA polymerization 
activity of these mutants, suggesting that it is important for other steps of reverse 
transcription and retroviral replication. 
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Structural defect of the MLV RT thumb domain mutants.  As indicated 
above, we performed Western blot analysis for all the mutants to normalize DNA 
polymerization activity.  Western blot of wild type virus with anti-MLV CA antibodies 
revealed two major bands corresponding to processed CA protein (p30) and unprocessed 
gag polyprotein (p65) (Fig. 5).  Most of the mutants demonstrated a relative ratio of these 
two bands that was similar to the wild type, indicating that processing of the gag proteins 
was not altered by mutations in MLV RT (data not shown).  Interestingly, the ratio of 
processed CA protein (p30) and unprocessed gag polyprotein (p65) bands of the R301P, 
W313A, and W313D mutants were smaller than for wild type, suggesting a processing 
defect (Fig. 5).  This processing defect may be a result of the altered folding of the 
mutant RTs.  The overall RT folding could affect protease folding and as a result 
decrease processing.  Alternatively, mutations in RT may decrease incorporation of the 
gag-pol proteins into viral particles (possibly because of altered RT folding), providing 
less protease in viral particles to process gag proteins.  However, the unprocessed gag-pol 
band could be detected in the W313A and W313D mutants, suggesting that it could be 
incorporated into viral particles (Fig. 5).   
Mutational analysis of the primer grip of MLV RT.  In addition to the thumb 
domain mutants, we performed random mutagenesis of L269 of the primer grip in MLV 
RT.  Previous in vitro studies showed that alanine substitution of the analogous M230 in 
HIV-1 RT displayed higher misincorporation fidelity in comparison to the wild type 
HIV-1 RT in vitro (58).  A total of 8 mutants were tested at the L269 position of MLV 
RT (Fig. 3).  With the exception of L269T, all mutations resulted in undetectable viral 
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titers (> 10,000-fold reduction) (Table 2).  L269T mutant resulted in reduced titer (7.5% 
of wild type), but did not change the accuracy of DNA synthesis (Table 2).     
DISCUSSION 
 The importance of the thumb domain of HIV-1 RT has been previously 
documented.  It has been shown that the thumb domain of HIV-1 RT is important for 
processivity (2, 5, 13), fidelity in vitro (2, 4, 5), affinity for template-primer complex (2, 
4), and RNase H cleavage (13, 46).  It has also been proposed that the thumb domain of 
HIV-1 RT serves as a “helix clamp” to hold the template-primer complex and as a 
“protein sensor” of structural alterations in the DNA minor groove upstream of the RT 
active site (21, 22, 35).  Despite the importance of the thumb domain for RT functions, 
the thumb domain of other RTs has not been identified or characterized.   
 In the present study, we identified the minor groove binding helix of the thumb 
domain of MLV RT based on sequence alignment and in vivo mutational analysis.  
Sequence alignment of 40 RTs revealed a highly conserved G-X-X-X-W/F/Y motif.  This 
motif points out the position of the minor groove binding helix not only in MLV RT but 
also in other RTs (Fig.1).  This hypothesis was further supported by the fact that amino 
acids adjacent to this motif are generally conserved within each group of retroviruses and 
lack the presence of prolines.  The aligned sequence also includes the α-helix I of HIV-1 
RT (277R-Q-L-C-K-L-L283) (25).  This sequence is only conserved in three RTs among 
the 40 compared in this study (HIV-1, HIV-2, and SIV).  However, the region which is 
aligned to the α-helix I possesses several semiconserved amino acids P-L-Y-X-X-X-K in 
other RTs (Fig. 1).  The lack of high homology in this region is consistent with a previous 
mutagenesis study of the α-helix I in HIV-1 RT.  Mutation of amino acids of the α-helix 
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I did not affect RT functions as mutations of amino acids of the α-helix H (3).  It must to 
be noted that a different DNA binding motif that is present in HIV-1 RT thumb domain 
was previously described (22).  This motif consists of HIV-1 RT amino acids 259K-L-V-
G-K-L-(X)16-K-L-L-R284.  However, this motif is not conserved in retroviruses and 
could not be used to define the thumb region.       
 Further mutational analysis performed in the current study revealed the 
importance of the minor groove binding helix of MLV RT thumb domain for fidelity of 
DNA synthesis.  This result was in agreement with previous in vitro data for HIV-1 RT.  
For instance, substitution of the F309 residue of MLV RT with alanine increased the 
mutation rate by 2.8-fold (Table 1).  The analogous mutation in HIV-1 RT (W266A) 
resulted in a 3.2-fold increase in the mutation frequency measured by a forward mutation 
assay in vitro (4).  The overall decrease in fidelity correlated with an increase in the rate 
of frameshift mutations by W266A, W266I, and W266V mutants of HIV-1 RT (2).  
Mutations of the R301 position of MLV RT that resulted in virus with detectible titer 
increased mutation frequencies during retroviral DNA synthesis by up to 1.9-fold (Table 
1).  This observation was consistent with the previously reported 1.9-fold increase in 
mutation rate in vitro of the R258A mutant of HIV-1 RT (4).  The estimation of the 
mutation frequency of L312R mutant of MLV RT showed a 2-fold increase in 
comparison to the wild type.  Mutation of the same position in HIV-1 RT (Q269A) 
displayed a similar 2.5-fold increase in mutation frequency in vitro (4).   
 The results of vertical scanning mutagenesis of the G305 in the current study 
supported our sequence alignment and indicated that all tested substitutions of the G305 
could not be tolerated during retroviral replication.   
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Mutational analysis data of the minor groove binding helix of MLV RT also well 
correlated with the proposed interactions of the this helix and the primer strand (Fig. 2C).  
It was proposed that residue F309 makes favorable hydrophobic "stacking" interaction 
with the sugar atoms of nucleotides in the primer strand.  Mutation F309W retains the 
same interaction with the primer strand.  However, F309T and F309V provide some 
hydrophobic interaction with the sugar in the primer strand and therefore these mutant 
viruses retain considerable viral titers.  Mutation F309A contains also a hydrophobic side 
chain, however it is too small to provide necessary interactions.  The F309H, F309I, 
F309L and F309N mutations resulted in the server steric clash between side chain atoms 
and the primer strand and therefore result in very low viral titers.  
The G305 form the van der Waals contact with the sugar ring oxygen atom of the 
nucleotide in the primer strand.  It is conceivable that even the smallest amino acid 
substitution at the G305 position tested in this study (G305V) will push the minor groove 
binding helix away from the primer by at least 2 angstroms and disrupt interactions of the 
DNA primer not only with G305 (G262 in HIV-1 RT), but also with F309 (W266 in 
HIV-1 RT).  Previous data indicated that disruption of these interactions by mutations at 
G262 and W266 residues significantly decreased the processivity of HIV-1 RT (2, 5, 13).  
Additionally, mutants of G262 and W266 positions have been shown to have a defect in 
strand-transfer reactions and specificity of the PPT cleavage  (13, 46).    
  Recently, we developed an in vivo assay to study the effect of mutations in MLV 
RT on template switching frequency during reverse transcription (54).  In that study we 
tested several thumb domain mutants of MLV RT.  The results indicated that R301Q, 
R301S, and F309W did not affect the frequency of template switching.  Again, it was 
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consistent that substitutions to amino acids which are present in HIV-1 RT at the same 
positions, did not change the function of RT.  The R301L and F309A mutants decreased 
the ability of MLV RT to switch templates during reverse transcription.  The proposed 
dynamic copy-choice model suggested that RNase H activity is one of the factors in 
determining the frequency of template switching.  Perhaps, R301L and F309A possess a 
deficiency in RNase H activity and as a result decrease template switching frequency.  
The R309H mutant displayed an increase in template switching frequency.   For this 
particular mutant it is possible that the RNase H activity is not affected to the same extent 
as for R301L and F309A, but template affinity might be decreased resulting in more 
frequent template switching events.   
 Vertical scanning mutagenesis of L269 in MLV RT primer grip presented in this 
study showed that almost any substitutions of this amino acid resulted in noninfectious 
virus.  These data is in agreement with two observations.  First, only leucine or metionine 
residues are present at this position in all 40 RTs analyzed in Fig. 1.  Second, despite the 
fact that F227, W229 and L234 of the HIV-1 RT primer grip are part of the binding 
pocket for non-nucleoside RT inhibitors, no drug resistant mutations were detected in the 
primer grip region (53).  Recent in vitro data indicated that mutations of the primer grip 
in HIV-1 RT, including M230A, could increase misinsertion fidelity in vitro (58).  The 
L269A, a similar mutant in MLV RT tested in this study, did not display any viral titer 
(Table 2).   
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Table 1.  Effects of mutations of the MLV RT thumb region on the frequency of 
lacZ inactivation. 
 
MLV RT 
Genotype 
No. 
of 
Expts. 
 
No. Mutant 
Colonies/ 
Total Coloniesa 
Frequency 
of lacZ 
Inactivation 
(%S.E.)b 
Relative 
Change in 
Inactivation 
of lacZc 
Relative 
Viral 
Titerd 
WT 7       227/3,953     5.9 ± 0.4 1.0 1.00 
      
R301H 2         79/785     9.5 ± 0.1 1.6 0.02 
R301I 2         44/382   11.5 ± 0.5 1.9   0.005 
R301L 2         96/1,536     6.6 ± 0.9 none 0.02 
R301P 1           NCe NAf NA < 0.0001 
R301Q 2       216/2,430     8.8 ± 0.5 1.5 0.30 
R301S 2       141/1,696     9.1 ± 2.1 1.5 0.05 
R301V 2       101/910     9.8 ± 2.1 1.7 0.01 
      
G305 D, E, F, 
I, N, Q, R, V 1           NC
 NA NA < 0.0001 
      
F309A 2       260/1,802   13.7 ± 0.3 2.8 0.02 
F309H 2         40/780     5.3 ± 0.3 none 0.03 
F309I 2         34/366     9.1 ± 0.2 1.7 0.07 
F309L 3           NC         NA NA < 0.001 
F309N 2         65/490   13.3 ± 0.9 2.3 0.02 
F309P 1           NC         NA NA < 0.0001 
F309T 2       109/1,073     9.3 ± 1.1 1.6 0.13 
F309V 2         36/449     7.7 ± 0.7 1.3 0.12 
F309W 2          27/693     3.9 ± 0.1 0.7 0.18 
      
L312E 1            NC NA NA < 0.0001 
L312R 2            8/82 9.7 NA < 0.001 
      
W313 A, D, Q 1            NC NA NA < 0.0001 
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a The number of mutant colonies that displayed a white colony phenotype and the 
total number of colonies that were observed in 1 to 7 independent experiments.   
b The frequency of lacZ inactivation was calculated as follows:  No. of mutant 
colonies in each experiment ÷ by total number of colonies × 100%.  The standard error of 
the mean (SE) was determined by using the Sigma Plot 5.0 program.  
c The relative change in the frequency at which the lacZ gene was inactivated was 
calculated as follows: frequency of lacZ inactivation observed with mutant MLV RT ÷ by 
frequency of lacZ inactivation observed with wild type MLV RT in the same experiment.  
Statistical analysis using a Two-sample T-Test showed that R301H, R301I, R301Q, 
R301S, R301V, F309A, F309I, F309N, F309T, F309V, F309W mutants of MLV RT 
displayed a significantly different mutant frequency in comparison to the wild type MLV 
RT (P < 0.05).  The mutant frequency obtained with the R301L and F309H mutants of 
MLV RT was not significantly different from the wild type MLV RT (P > 0.05).   
d Virus titer for each experimental group was determined by serial dilutions.  The 
average virus titer obtained with wild type MLV RT was 3.1 × 104 CFU/ml.  The relative 
virus titer represents a ratio of the virus titer of mutant MLV RT obtained in each 
experiment divided by the virus titer obtained with wild type MLV RT in parallel 
experiments. 
e NC represents no colonies present after G418 selection signifying titers less than 
10,000 CFU/ml. 
f NA represents not applicable since the relative change in the inactivation of lacZ 
gene could not be determined due to the absence or low number of colonies after G418 
selection. 
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Table 2.  Effects of mutations of the primer grip of MLV RT on the frequency of 
lacZ inactivation 
 
MLV RT 
Genotype 
No. 
of 
Expts. 
 
No. Mutant 
Colonies/ 
Total Coloniesa 
Frequency 
of lacZ 
Inactivation 
(%S.E.)b 
Relative 
Change in 
Inactivation 
of lacZc 
Relative 
Viral 
Titerd 
WT 2       50/1096     4.4 ± 0.4 1.0 1.00 
L269T 2       53/904 6.3 ± 0.9 none 0.075 
L269 A, G, H, 
N, Q, R, S 1           NC
e NAf NA < 0.0001 
 
a The number of mutant colonies that displayed a white colony phenotype and the 
total number of colonies that were observed in 2 independent experiments.   
b The frequency of lacZ inactivation was calculated as for table1. 
c The relative change in the frequency at which the lacZ gene was inactivated was 
calculated as for table 1.  Statistical analysis using a Two-sample T-Test showed that 
L269T mutant of MLV RT did not display a mutant frequency significantly different 
from the wild type MLV RT (P = 0.199).   
d Virus titer for each experimental group was determined by serial dilutions.  The 
average virus titer obtained with wild type MLV RT was 1.5 × 104 CFU/ml.  The relative 
virus titer represents a ratio of the virus titer of mutant MLV RT obtained in each 
experiment divided by the virus titer obtained with wild type MLV RT in parallel 
experiments. 
e NC represents no colonies present after G418 selection signifying titers less than 
10,000 CFU/ml. 
f NA represents not applicable since the relative change in the inactivation of lacZ 
gene could not be determined due to the absence of colonies after G418 selection. 
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FIGURE LEGENDS 
 FIG. 1. Amino acid sequence alignment of primer grip and thumb domain 
region of retroviral reverse transcriptases.  Black shading indicates primer grip region 
and conserved G-X-X-X-W/F/Y (aromatic amino acid) motif of the minor groove 
binding helix of the thumb domain.  Gray shading indicates conserved and 
semiconserved amino acids that are present in MLV RT.  An open box designates the α-
helix H of HIV-1 RT based on crystal structure data (25).  The underlined amino acids 
are conserved or semiconserved between MLV RT and HIV-1 RT.  The accession 
number is a number assigned to each sequence in the protein database. G305 and F309 of 
MLV RT and G262 and W266 of HIV-1 RT are labeled by correspondent numbers. 
 FIG. 2. Model of the MLV RT Thumb domain.  (A) A ribbon representation of 
the superimposed structure fingers and thumb domain of the MLV RT over the 
corresponding domain of the HIV-1 RT.  The white ribbon represents the HIV-1 RT. The 
yellow ribbon represents the crystal structure of MLV RT.  The magenta colored ribbon 
shows the homology model of the MLV RT thumb region.  Residues 16 to 22 of the 
primer strand are shown as cyan bonds.  (B) The primer binding pocket of HIV-1 RT 
(25).  Residues that were used for homology modeling study is shown by ribbon 
representation. The rest of the residues in the primer-binding pocket is shown as c-alpha 
atom trace.  Residues 16 to 22 of the primer strand are shown as cyan bonds. Yellow 
colored ribbon represents loops where amino acid Q277 in a loop and amino acids TPK 
(293-295) of MLV RT were positioned.  (C) Interactions of the minor groove binding 
helix of MLV RT with the primer. Minor groove binding helix of MLV RT is shown as a 
ribbon representation. The primer nucleotides are shown as atom-based color-coded 
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bonds. The residues, R297, R301, E302, G305 and F309 are labeled. The c-alpha atom of 
G305, the side chain atoms of F309, and oxygen atom of the fourth nucleotide upstream 
of the 3’ end in the primer strand, and the sugar ring atoms of the third nucleotide of the 
3’ end in the primer strand are shown as van der Waals spheres. 
FIG. 3.  Mutational analysis of the minor groove binding helix of MLV RT. 
(A) Protocol for in vivo assay to identify structural determinants of MLV RT important 
for fidelity.  The pLGPS construct expresses the MLV gag and pol from a truncated viral 
LTR.  The wild-type or mutated pLGPS constructs were separately cotransfected (Tf) 
with pSVα3.6 into the ANGIE P cells.  ANGIE P, a D17-based cell line, expressed pGA-
1 and pSV-A-MLV-env. The pGA-1 vector contains LTRs and all cis-acting elements of 
MLV.  The pGA-1 also encodes for β-galactosidase reporter gene (lacZ).  The lacZ and 
neo are transcribed from the LTR promoter and IRES of encephalomyocardidtis virus is 
used to express neo.  Ψ designates MLV packaging signal.  The pSV-A-MLV-env 
construct expresses the amphotropic MLV envelope from a truncated MLV LTR and the 
SV40 promoter enhancer. The virus produced was used to infect D17 cells.  The infected 
cell clones resistant to G418 were stained with X-Gal and frequencies of inactivation of 
lacZ reporter gene were determined.  (B) Mutants of the primer grip and thumb domain 
of MLV RT.  Primary sequence containing the primer grip and the minor groove binding 
helix of the thumb domain is shown.  The numbers above the primary sequence indicate 
the amino acid positions in the primary sequence.  The substitution mutations analyzed at 
each amino acid position are indicated below the primary sequence with downward 
arrows. 
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 FIG. 4.  RT activities for virion-associated RTs.  The activities shown are 
relative to the RT activity determined for the wild-type MLV RT (set 100%).  The results 
represent an average of two to three independent experiments.  The error bars represent 
the standard error of the mean.  
 FIG. 5.  Decreased processing of mutant viruses.  A representative Western 
blot analysis is shown for the wild-type (WT) virus and viruses containing mutation in 
RT (R301P, W313A, and W313D).   Unprocessed gag-pol, unprocessed gag (p65) and 
processed CA (p30) bands are indicated by arrows.   
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C-Type Retroviruses                   accession no. 
Moloney murine leukemia virus           AAC82568.1 YLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTK 
Gibbon leukemia virus                   AAC80264.1 YLGYLLKEGKRWLTPARKATVMKIPAPTTPRQVREFLGTAGFCRLWIPGFASMAAPLYPLTK 
Phascolarctos cinereus (Koala)          AAF15098.1 YLGYLLKGGKRWLTPARKATVMKIPTPTTPRQVREFLGTAGFCRLWIPGFASLAAPLYPLTR 
Porcine endogenous retrovirus           CAB65341.1 YLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTK 
Baboon endogenous virus                 BAA89659.1 YLGYILSEGKRWLTPGRIETVARIPPPRNPREVREFLGTAGFCRLWIPGFAELAAPLYALTK 
Feline leukemia virus                   AAA93092.1 YLGYSLKDGQRWLTKARKEAILSIPVPKNPRQVREFLGTAGYCRLWIPGFAELAAPLYPLTR 
Spleen necrosis virus                  unpublished YLGFKIHKGSRTLSNSRTQAILQIPVPKTKRQVREFLGTIGYCRLWIPGFAELAQPLYAATR  
Lentiviruses 
Human immunodeficiency virus type 1     Ref.26     WMGYELHPD-KWTVQPIVLPEKDSW---TVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGT 
Human immunodeficiency virus type 2     AAA64576.1 WMGYELWPT-KWKLQKIQLPQKEVW---TVNDIQKLVGVLNWAAQIYPGIKTKHLCRLIRGK 
Simian immunodeficiency virus           AAA74707.1 WLGYTLHPD-KWQLQKIELPNIDDEI--TVNQLQKLIGVLNWASQIYSGIKTKELCKCIRGT 
Puma lentivirus 14                      AAA67168.1 WMGYTLYPN-KWTIQKTKLDIPEVP---TLNQLQKLAGVINWATQNVGGIKIKALTELMKGN 
Visna virus                             AAA17524.1 WLGFELHPE-KWKFQKHTLPEITEGPI-TLNKLQKLVGDLVWRQSLIGKSIPNILKLMEGDR 
Ovine lentivirus                        AAA66821.1 WLGFELHPE-KWRFQKHTLPEIKEGTI-TLNKLQKLVGDLVWRQSLIGKSIPNILKLMEGDR 
Jembrana disease virus                  AAA64389.1 WLGYELTPK-RWRFQPRQIKIKKVV---TVNELQQMIGNCVWVQPEV-KI-PLS-PLSDLLK 
Caprine arthritis-encephalitis virus    AAA91826.1 WLGFELHPQ-TWKFQKHTLPELTKGTI-TLNKLQKLVGELVWRQSIIGKSIPNILKLMEGDR 
Feline immunodeficiency virus           AAA43071.1 WMGYELHPL-TWSIQQKQLEIPERP---TLNELQKLAGKINWASQTIPDLSIKELTNMMRGD  
Equine infectious anemia virus          AAA43004.1 WLGYQLCPE-NWKVQKMQLDMVKNP---TLNDVQKLMGNITWMSSGVPGLTVKHIAATTKGC 
HTLV/BLV Viruses 
Human T-cell lymphotropic virus type 1  AAA85843.1 FLGQIISPN--HLTYDAVPTVPIRSRW-ALPELQALLGEIQWVSKGTPTLRQPLHSLYCALQ 
Human T-cell lymphotropic virus type 2  AAB59885.1 FLGQVISPN--HITYESTPTIPIKSQW-TLTELQVILGEIQWVSKGTPILRKHLQSLYSALH 
Simian T-cell lymphotropic virus type 2 AAB58786.1 FLGQVISPD--HITYETTPTIPMKSQW-TLAELQTVLGEIQWVSKGTPILRKHLQCLYSALR 
Simian T-cell lymphotropic virus        CAA68894.1 FLGQVISQD--CITYETLPSIHIKSTW-SLAELQSMLGELQWVSKGTPVLRSSLHQLYIALR 
Bovine leukemia virus                   AAC82587.1 FLGQMVHNQ--IVTYQSLPTLQISSPI-SLHQLQAVLGDLQWVSRGTPTTRRPLQLLYSSLK 
Bovine syncytial virus                  AAB68770.1 FLGFSISQNGRGLTDSYKQKLMDLQPPTTLRQLQSILGLINFARNFLPNFAELVAPLYQLIP 
Simian foamy virus type 3               AAA47796.1 FLGFNITKEGRGLTETFKQKLLNITPPRDLKQLQSILGLLNFARNFIPNFSELVKPLYNIIA 
D-Type Retroviruses 
Mason-Pfizer monkey virus               AAA47711.1 YLGFELNGP-KITNQKAVIRKDKLQ---TLNDFQKLLGDINWLRPYLKLTTGDLKPLFDTLK 
Simian SRV-2 type D retrovirus          AAA47562.1 YLGFQINGP-KITNQKAVIRRDKLQ---TLNDFQKLLGDINWLRPYLHLTTGDLKPLFDILK 
Simian type D virus 1                   AAC97565.1 YLGFQINGP-KIINQKAVIRHDHLK---TLNDFQKLLGDINWLRPYLKLTTGELKPLFDILK 
Ovine pulmonary adenocarcinoma virus    AAD45226.1 YLGFSLYPR-VYNTQLVKLQTDHLK---TLNDFQKLLGDINWIRPYLKLPTYTLQPLFDILK 
Simian sarcoma virus                    AAA66453.1 YLGFELHHQQVF-TPRVCLKTDHLK---TLNDFQKLLGDIQWLRPYLKLPTSALVPLNNILK 
Avian and other retroviruses 
Multiple sclerosis assoc. retrovirus    AAB66528.1 YLGLKLSKGTRALSEERIQPILAYPHPKTLKQLRGFLGITGFCRKQIPRYTPIARPLYTLIR 
Walleye epi. Hyp. virus type 2          AAC59311.1 YLGQLLSDRGREILPDRKETVSQFSSPTTVRQVRAFLGLAGYCRHWIPDYSEQSKYLEELLK 
Walleye epi. Hyp. virus type 1          AAC59310.1 YLGQLISKAGRDILPERKKTVSQFAAPTTVRQVRAFLGLAGYCRHWIADYSENSKHLEELLK 
Rous sarcoma virus                      CAA48535.1 YLGYKLGST--YVAPVGLVAEPRIA---TLWDVQKLVGSLQWLRPALGIPPRLMGPFYEQLR 
Avian leukosis virus                    AAA91269.1 YLGYKLGST--YVAPVGLVAEPRIA---TLWDVQKLVGSLQWLRPALGIPPRLMGPFYEQLR 
Avian myeloblastosis virus              AAB31929.1 YLGYKLGST--YVAPVGLVAEPRIA---TLWDVQKLVGSLQWLRPALGIPPRLRGPFYEQLR 
Lymphoproliferative disease virus       AAA62195.1 YLGWRVMET--GIAPLTVQLPETV---TNLVQLQRLLGIIQWLKPILSLRPEQLQVFYDLLK  
Mouse mammary tumor virus               BAA03767.1 YLGTYIQGD--VVSYQKLQIRTDKLR--TLNDFQKLLGNINWIRPFLKLTTGELKPLFEILN 
Avian myeloblastosis-assoc virus type 1 AAA46304.1 YLGYKLGST--YVAPVGLVAEPRIA---TLWDVQKLVGSLQSVRPALGIPPRLMGPFYEQLR 
Nonretroviral RTs 
  Hepatitis B virus                    AA69721 FMGYVIGSWGTLPQEHIVLKIKQCFRKLPVNRPIDWKVCQRIVGLLGFAAPFTQCGYPALMPLYACIQ 
  Cauliflower mosaic virus                   Q02964 FLGLEIDEGTHKPQGHILEHINKFPDTLEDKKQLQRFLGILTYASDYIPKLAQIRKPLQAKLK 
305     309     
262     266     
--------- 28-39a.a.--------------GXXXW/F/Y motif 
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ABSTRACT 
The antiretroviral nucleoside analog 2′,3′-dideoxy-3′-thiacytidine (3TC) is a 
potent inhibitor of wild-type human immunodeficiency virus type 1 (HIV-1) reverse 
transcriptase (RT).  A methionine-to-valine or methionine-to-isoleucine substitution 
at residue 184 in the HIV-1 YMDD motif, which is located at the RT active site, 
leads to a high level of resistance to 3TC.  We sought to determine whether 3TC can 
inhibit the replication of wild-type murine leukemia virus (MLV) RT, which 
contains V223 at the YVDD active site motif, and of the V223M, V223I, V223A, and 
V223S mutant RTs.  Surprisingly, the wild-type and all four of the V223 mutants of 
MLV RT were highly resistant to 3TC.  These results indicate that determinants 
outside the YVDD motif of MLV RT confer a high level of resistance to 3TC.  
Therefore, structural differences among similar RTs might result in widely 
divergent sensitivities to antiretroviral nucleoside analogs. 
INTRODUCTION 
Currently, 14 antiviral drugs have been approved for clinical use to combat 
human immunodeficiency virus type 1 (HIV-1) infections (11, 54).  When used in 
combination, many of these drugs have been shown to prolong the life expectancy of 
infected individuals and slow the progression of AIDS (12, 14, 20, 21, 40, 42).  Most of 
these drugs, both nucleoside and nonnucleoside inhibitors, have been designed to target 
reverse transcriptase (RT) (2, 10, 53).  One of the compounds used in combination 
therapy is the nucleoside analog 2′,3′-dideoxy-3′-thiacytidine (3TC) (4, 20, 21, 37, 51).  
The triphosphate form of 3TC inhibits reverse transcription through chain termination of 
DNA polymerization, a function carried out by RT, and therefore has been observed to be 
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a potent inhibitor of both HIV type 1 and type 2 replication (2, 9, 10).  In addition to the 
clinical benefits (20, 21, 37, 46) associated with the use of this nucleoside analog, 3TC 
exhibits low toxicity, even at millimolar concentrations (7, 9, 15, 36).   
All of the drugs being used for therapy to combat HIV-1 infections eventually 
result in drug-resistant mutants, thereby allowing for the progression of the disease.  
Resistance to 3TC is no exception and is characterized by a mutation at the methionine 
184 position of the Tyr-Met-Asp-Asp (YMDD) motif found in HIV-1 RT (5, 17, 31, 48, 
55).  The YXDD motif, where X is a variable amino acid, is highly conserved among the 
many viral RNA polymerases as well as RNA-dependent DNA polymerases (43).  For 
example, Rous sarcoma virus RT contains the YMDD motif, the RTs of retroelements 
such as 297 (Gypsy-like group) and Int 32 (Line-like group) contain both the YLDD and 
YADD sequences, and the poliovirus RNA polymerase contains the YGDD motif (43).  
Mutations in the YXDD motif can abolish enzymatic activity and alter the processivity 
and fidelity of RT (3, 6, 23, 27, 39).  The prevalent mutation in HIV-1 RT associated with 
3TC resistance is the M184V substitution (17, 48, 55), which confers a level of resistance 
1000 times greater than that displayed by the wild-type enzyme (17, 55).  It has been 
observed that the M184I variant, which is resistant to 3TC but is less catalytically active, 
is selected first after initiation of 3TC treatment (5, 6, 31, 55), and then is replaced by the 
M184V variant after long-term treatment with 3TC. 
Mutations in the motif analogous to the HIV-1 RT YMDD domain are also 
correlated with resistance to 3TC in other retroviruses.  The YVDD, YIDD, and YTDD 
motifs are selected during 3TC treatment of cells infected with simian immunodeficiency 
virus (SIV) or feline immunodeficiency virus (FIV) (8, 49).  In addition, the YVDD and 
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YIDD motifs arise during 3TC treatment of hepatitis B virus (HBV)-infected cells and 
patients (1).  The selection for mutations in the YXDD motif in other retroviruses as well 
as in HBV has suggested that this determinant is widely associated with 3TC sensitivity.   
Other mutations in HIV-1 and FIV RTs have been implicated to confer dual 
resistance to 3TC and other nucleoside analogs.  Specifically, the E89G and G333E 
mutations in HIV-1 RT are correlated with dual resistance in tissue culture to 3TC and 
either phosphonoformic acid or 3′-azido-3′-deoxythymidine (AZT), respectively (29, 45).  
The K65R mutation in HIV-1 RT is associated with resistance to 3TC and 2′,3′-
dideoxycytidine (ddC) (19).  Finally, the P156S mutation in FIV RT appears to confer 
resistance to both AZT and 3TC (50). 
Although HIV-1 and MLV RTs share only ~25% amino acid sequence identity, 
the two proteins are structurally similar (18).  Comparison of the finger and palm 
domains in HIV-1 and MLV RT crystal structures reveals similar tertiary structures (18, 
25, 34).  In addition, many of the sequence motifs present in HIV-1 RT, such as the 
YXDD motif, the dNTP-binding site, and the conserved Leu-Pro-Gln-Gly (LPQG) motif, 
are also present in MLV RT.  Importantly, the antiretroviral nucleoside analogs AZT, 
ddC, 2′,3′-dideoxyinosine (ddI), and 2′,3′-didehydro-3′-deoxythimidine (d4T), which 
inhibit HIV-1 RT, also inhibit MLV RT (52).  Therefore, since wild-type MLV RT 
contains the YVDD motif, it was expected and recently shown to be resistant to 3TC 
(44). 
Based on the similarities between the HIV-1 and MLV RTs, we hypothesized that 
the YMDD mutant of MLV RT would be sensitive to 3TC and the YIDD mutant would 
be resistant.  To test this hypothesis, we generated viruses containing wild-type MLV RT 
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as well as several mutants at position V223 within the YVDD motif and compared the 
titers of these viruses in several different target cells in the presence or absence of 3TC. 
RESULTS AND DISCISSION 
MLV mutants, target cells, and the ANGIE P cell line.  The construction of the 
V223A, V223I, V223M, and V223S mutants was described previously (23).  The mutants 
were generated from the parent plasmid pLGPS (Fig. 1A), which expresses the MLV gag 
and pol genes from a truncated MLV long terminal repeat (∆LTR) promoter (41). 
 The targets of infection in this study included the murine fibroblast cell line NIH 
3T3 and the human osteosarcoma cell line 143B (both obtained from the American Type 
Culture Collection).  The ANGIE P cell line (Fig. 1B) is a D17-based (dog osteosarcoma) 
cell line expressing the construct pSV-A-MLVenv (obtained from the NIH AIDS 
Research and Reference Program) and pGA-1, an MLV-based retroviral vector (Fig. 1A) 
(23, 38).  The expression construct pSV-A-MLVenv encodes the amphotropic MLV 
envelope gene, whereas pGA-1 expresses the bacterial β-galactosidase gene (lacZ) from 
the LTR promoter.  In addition, pGA-1 also contains the neomycin phosphotransferase 
gene (neo), which is utilized as a selectable marker during infection.  All cells were 
maintained in Dulbecco’s modified Eagle’s medium (ICN Biochemicals) supplemented 
with penicillin (50 U/ml; Gibco), streptomycin (50 µg/ml; Gibco), and bovine calf serum 
(6% for ANGIE P and 143B cells or 10% for NIH 3T3 cells; HyClone Laboratories).  
 Protocol for determining sensitivity of MLV RT to 3TC.  The approach used to 
determine the sensitivity of MLV RT to 3TC is outlined in Fig. 1B.  Briefly, either wild-
type or mutated pLGPS along with pSVα3.6, a plasmid that confers resistance to ouabain 
(30), were cotransfected into the ANGIE P cell line.  Transfections were carried out by 
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the previously described dimethyl sulfoxide-Polybrene method (28) and the transfected 
cells were then selected for resistance to 10-7 M ouabain.  
 To determine the sensitivity of the MLV RTs to 3TC, we separately pooled and 
expanded more than 500 ouabain-resistant colonies for the wild-type and V223 mutants.  
For each pLGPS construct, 5 × 106 ouabain-resistant cells were plated on 100-mm-
diameter dishes and the medium was changed 24 h later.  Virus was harvested after 
another 24 h and serially diluted.  In the presence of Polybrene (50 µg/ml), the virus was 
used to infect either NIH 3T3 or 143B cells for 4 h.  The target cells were plated at a 
density of 1-2 × 105 cells per 60-mm-diameter dish.  In experiments conducted in the 
presence of the drug, the target cells were incubated with 10 µM 3TC 4 h prior to 
infection, 4 h during infection, and 24 h post infection.  The 3TC concentration used in 
this study was 15- to 4000-fold higher than the mean 50% inhibitory concentration [IC50], 
ranging between 2.5 nM to 0.67 µM, which was previously shown to inhibit several 
different strains of HIV-1 (9).  The infected cells were then subjected to selection with 
G418, an analog of neomycin (600 µg/ml for 143B and D17 cells and 1.2 mg/ml for NIH 
3T3 cells) 24 h after infection.  The effect of 3TC treatment on MLV replication (wild-
type and V223 mutants) was determined by the number of drug-resistant colonies 
obtained in the presence or absence of 3TC. 
 Comparison of viral titers in the presence or absence of 3TC.  Viral titers were 
determined by quantitation of G418-resistant NIH 3T3 and 143B cells after infection (the 
data are summarized in Table 1).  ANGIE P cells transfected with wild-type pLGPS or 
the V223A, V223I, V223M, or V223S mutant were previously shown to produce 
infectious viral particles, and target cells infected with these viruses were expected to 
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confer resistance to G418 (23).  Two to four independent infections of NIH 3T3 and 
143B cells, in the absence or presence of 3TC, were performed with virus containing 
either the wild-type pLGPS or one of the four V223 mutants. 
Infection of NIH 3T3 cells with the wild-type virus harvested from a single pool 
produced titers that ranged from 2.7 × 104 to 1.3 × 105 CFU/ml in the absence of 3TC.  
Treatment of the target cells with 3TC had no significant effect on the titers of the wild-
type virus (82%, relative to the untreated control).  Similarly, infection of NIH 3T3 cells 
with the V223M mutant produced titers that ranged from 1.6 × 102 to 9.2 × 104 CFU/ml 
in the absence of 3TC after harvesting virus from two different virus-producing pools.  
Treatment of the target cells with 3TC did not substantially affect the titers of the V223M 
mutant virus (57%, relative to the untreated control) when compared to the inhibition of 
the luciferase-expressing HIV-1-based vector pNLuc (Fig. 2C).  The 2-fold change 
observed in the titers in the absence or presence of 3TC is probably not biologically 
relevant due to the inherent variation that occurs during infections (23).  We also assessed 
the sensitivity to 3TC of other V223 mutants (V223A, V223I, and V223S) in NIH 3T3 
cells; the results were similar to those obtained with the wild-type and V223M mutant 
viruses.  In summary, viral titers in the presence or absence of 3TC varied by only 2-fold, 
suggesting that 3TC did not substantially inhibit either the wild-type or V223 mutant RTs 
during infection of NIH 3T3 cells. 
To determine whether the lack of inhibition to MLV replication with 3TC 
treatment was specific to NIH 3T3 cells, we also tested infection of 143B cells and D17 
cells.  Infection of 143B cells with virus containing either the wild-type or V223M 
mutant RT produced results similar to those obtained with NIH 3T3 cells.  Virus obtained 
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from wild-type pLGPS produced viral titers that ranged from 3.4 × 102 to 1.9 × 103 
CFU/ml in the absence of 3TC.  Treatment of the target cells with 3TC had no significant 
effect on the titers of the wild-type virus (110%, relative to the untreated control).  In 
addition, infection of 143B cells with virus containing the V223M mutant RT produced 
viral titers ranging from 1.0 × 101 to 2.5 × 102 CFU/ml in the absence of 3TC and 0.5 × 
101 to 1.3 × 102 CFU/ml in the presence of 3TC (57%, relative to the untreated control).  
Similar results were obtained with D17 cells (data not shown).  
Activation of 3TC in target cells.  The results obtained with viruses generated 
and harvested from the ANGIE P cells that had been transfected with either the wild-type 
or V223 mutant constructs showed that all MLV RTs were resistant to 3TC (Table 1).  
There are two possible explanations for these results.  First, structural differences 
between MLV RT and HIV-1 RT might account for the resistance of MLV RT to 3TC.  
Second, the uptake and/or phosphorylation of the drug by the target cells might be 
inefficient.  To address these possibilities, we generated infectious HIV-1 particles and 
used them to infect the various target cells as previously described (32, 33) (Fig. 2A and 
2B).  Briefly, 293T (human embryonic kidney) cells were cotransfected with pNLuc and 
pSV-A-MLVenv.  Pseudotyped virus stocks were harvested and used to infect NIH 3T3, 
HeLa, 143B, and D17 cells in the presence or absence of 10 µM 3TC.  The target cells 
infected in the presence of drug were incubated with 3TC for 4 h prior to infection, 4 h 
during infection, and 24 h post infection.  Two days post infection, the cells were lysed 
and the amount of luciferase activity present in the lysates was measured with a 
luminometer (Tropix) (Fig. 2B). 
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Infection of NIH 3T3, 143B, and HeLa cells with the pNLuc-derived virus was 
decreased 20-fold by 3TC treatment (Fig. 2C).  The D17 cells exhibited a 4-fold decrease 
in pNLuc expression relative to no 3TC treatment.  Thus, in the same cell lines in which 
MLV infectivity was not substantially affected, HIV-1 infectivity was significantly 
reduced.  These results indicate that the lack of an effect of 3TC on MLV infectivity was 
not due to problems associated with the uptake, phosphorylation, or other mechanisms 
that interfered with the inhibitory activity of the nucleoside analog in these target cells.  
The less efficient inhibition of pNLuc expression in the D17 cells in comparison to the 
other target cells (Fig. 2C) could have been caused by either reduced uptake or 
phosphorylation of 3TC in D17 cells.  Alternatively, this cell line might actively export 
the nucleoside analog, thus reducing its efficacy.  Regardless of the mechanism, HIV-1 
infection of different cell types in vivo might display divergent susceptibilities to 3TC or 
other RT inhibitors.  Thus, the data obtained with the D17 cell line might have 
implications for drug therapy in HIV-1-infected patients. 
Mechanism of 3TC resistance in MLV RT.  3TC resistance arises in both 
retroviral (HIV-1, SIV, and FIV) and nonretroviral (HBV) polymerases with catalytic 
sites containing the YMDD motif (1, 8, 17, 31, 48, 49, 55).  This resistance usually 
results from a substitution of methionine to threonine, isoleucine or valine.  Based on 
these observations, we expected that the wild-type MLV RT containing the YVDD motif 
would be resistant (44) and the V223M mutant would be sensitive to 3TC.  It was 
therefore surprising that both the wild-type and the V223M mutant were highly resistant 
to 3TC.   
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The mechanism by which the M184V mutant of HIV-1 RT confers resistance to 
3TC is unclear.  The methionine-to-isoleucine substitution at position 184 in HIV-1 RT 
results in a repositioning of the template-primer complex, and this rearrangement might 
result in a misalignment of the 3TC triphosphate with the template, resulting in a 
decrease in the turnover rate (47).  Molecular modeling of the wild-type and M184I 
mutant of HIV-1 RT has also suggested that steric hindrance between the β-L-
oxathiolane ring of 3TC triphosphate and the β-branched amino acids (valine, isoleucine, 
and threonine) at position 184 interferes with 3TC binding (25, 47).  It is important to 
note that the proposed steric hinderance model does not preclude 3TC binding to RT in a 
mode that is unfavorable to its incorporation.  In this regard, Feng and Anderson (13) 
reported that 3TC triphosphate binds to the M184V mutant with a much higher Kd value 
(5.2 µM) relative to the wild type HIV-1 RT (0.24 µM).  Similarly, Wilson et al (56) 
suggested that β-L-2′,3′-dideoxy-5-fluoro-3′-thiacytidine , a nucleoside analog that is 
structurally similar to 3TC, binds with a higher affinity to the wild type HIV-1 RT than 
the M184V mutant.  However, Krebs and coworkers did not find a substantial difference 
in the Kd values for 3TC binding to wild type and M184V mutants (35).  Recent 
evidence indicates that the 3TC can bind to the M184V and M184I mutants of HIV-1 RT, 
which results in a conformational change in the enzyme that affects the nature of RNase 
H cleavages (16).   
The fact that both the YMDD and YVDD motifs are highly resistant to 3TC 
strongly suggests that other structural determinants of MLV RT may interfere with the 
nature of 3TC binding through steric hindrance.  The previous observation that MLV RT 
is sensitive to ddC (52) suggests that the steric hindrance involves the β-L-oxathiolane 
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ring of 3TC.  In accordance with the relatively low (~25%) amino acid sequence identity 
between the MLV and HIV-1 RTs (18), structural alterations at or near the active site not 
related to the YVDD motif of MLV RT may lead to steric hindrance and prevent 3TC 
binding.  A comparison of distances between residues of the YXDD motif and dNTP 
binding pocket of HIV-1 and MLV RTs reveals substantial differences (18, 24).  
Distances in MLV RT, specifically between the residues of the YVDD motif and K103, 
which is equivalent to K65 of HIV-1 RT (22), are more than 2 angstroms longer when 
compared to HIV-1 RT.  It should be noted that the K65 residue of HIV-1 RT is 
associated with dual resistance to 3TC and ddC (19).  These and other structural 
differences might contribute to the divergent sensitivities to 3TC.   
Additionally, amino acid differences between the MLV and HIV-1 RTs around 
the dNTP-binding pocket may also provide the steric hindrance needed to confer 3TC 
resistance.  Specifically, the MLV RT possesses a phenylalanine at position 155, which is 
equivalent to the tyrosine 115 in HIV-1 RT.  The Y115 of HIV-1 RT has been shown to 
interact with the ribose ring of a dNTP substrate (25).  Therefore, substitutions of the 
phenylalanine for the tyrosine in MLV RT dNTP binding site may alter the nature of 3TC 
binding.         
It is also conceivable that the structural differences near the active site or dNTP 
binding site between MLV and HIV-1 RTs, alter the affinity or nature of binding of 3TC 
triphosphate relative to dCTP by a mechanism not involving steric hinderance.  The 
nature of the structural differences that confer high-level resistance to 3TC despite the 
presence of a YMDD motif appears to be unique to MLV RT, since several other 
retroviral RTs as well as HBV polymerase display sensitivity to 3TC when the YMDD 
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motif is present (1, 8, 49).  Understanding the nature of the structural differences that lead 
to 3TC resistance in MLV RT might provide insights into the general mechanisms by 
which retroviral RTs acquire resistance to nucleotide analogs.   
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TABLE 1.  The effect of 3TC treatment on MLV replication 
 
Target 
cells 
MLV 
RT a 
 
Expt. 
no. 
-3TC titer 
(CFU/ml) b 
+ 3TC titer 
(CFU/ml) c 
+3TC 
relative titer 
(Mean ± S. E.) d 
NIH 3T3 WT 1 3.7 × 104 2.6 × 104 0.70 
  2 2.7 × 104 1.5 × 104 0.56 
  3 7.2 × 104 9.2 × 104 1.28 
  4 1.3 × 105 9.5 × 104 0.73 
  Avg   0.82 ± 0.16 
 V223M 1 2.9 × 102 1.4 × 102 0.48 
  2 1.6 × 102 1.0 × 102 0.63 
  3 9.2 × 104 6.9 × 104 0.75 
  4 2.4 × 104 1.0 × 104 0.42 
  Avg   0.57 ± 0.07 
 V223I 1 3.4 × 104 2.5 × 104 0.74 
  2 2.6 × 104 3.3 × 104 1.27 
  Avg   1.01 ± 0.27 
 V223A 1 1.3 × 102 1.9 × 102 1.46 
  2 2.1 × 102 2.0 × 102 0.95 
  Avg   1.21 ± 0.26 
 V223S 1 4.3 × 104 4.3 × 104 1.00 
  2 8.3 × 103 1.2 × 104 1.45 
  Avg   1.23 ± 0.23 
143B WT 1 1.9 × 103 1.4 × 103 0.74 
  2 3.4 × 102 5.8 × 102 1.70 
  3 4.3 × 102 3.5 × 102 0.8 
  4 1.2 × 103 1.3 × 103 1.10 
  Avg   1.10 ± 0.23 
 V223M 1 2.5 × 102 1.3 × 102 0.52 
  2 2.0 × 102 8.3 × 101 0.42 
  3 1.3 × 101 1.1 × 101 0.85 
  4 1.0 × 101 0.5 × 101 0.50 
  Avg   0.57 ± 0.09 
 
a The genotype of MLV virus generated from transfection of  pLGPS (wild-type 
or V223 mutants of MLV RT) into the ANGIE P encapsidating cell line.  
b The titer obtained from infections in the absence of 3TC.  The virus titer for 
each experimental group was determined by serial dilutions.  In experiments using NIH 
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3T3 target cells, four independent infections were performed with virus containing the 
wild-type or V223M mutant RT, whereas two independent infections were performed for 
the V223A, V223I, and V223S RTs.  In experiments using 143B target cells, four 
independent infections were performed with virus containing the wild-type or V223M 
mutant RT. 
c The titer obtained from infections in the presence of 3TC.  The virus titer for 
each experimental group was determined by serial dilutions.  Four independent infections 
were performed in the presence of 3TC (10 µM) as described in footnote b for virus 
containing either the wild-type or V223M RT.  The 3TC treatment included incubation of 
the target cells 4 h prior to infection, 4 h during infection, and 24 h post infection.  
d The +3TC relative titer was calculated as follows:  [titer obtained in the presence 
of 3TC] ÷ [titer obtained in the absence of 3TC].  S. E. represents the standard error. 
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FIGURE LEGENDS AND FIGURES 
 
FIG. 1.  Structures of MLV-based constructs and protocol used to determine 
sensitivity to 3TC.  (A) Structures of the MLV-based vector pGA-1 and the gag-pol 
expression construct pLGPS.  The pGA-1 vector contains both LTRs and all cis-acting 
elements of MLV and transcribes the E. coli lacZ and neo from the LTR promoter.  The 
internal ribosomal entry site (IRES) (26) of encephalomyocarditis virus is used to express 
neo.  The construct pLGPS expresses the MLV gag-pol gene from a truncated viral LTR.  
(B) Experimental protocol.  ANGIE P, a D17-based cell line expressing pGA-1 and a 
vector carrying the amphotropic MLV env gene (pSV-A-MLVenv), was separately 
transfected with either the wild-type (V223) or mutated (V223A, V223I, V223M, and 
V223S) pLGPS constructs.  Virus from pools of these transfected ANGIE P cells was 
harvested and used to infect target cells (NIH 3T3 or 143B cells) for 4 h in the presence 
or absence of 3TC (10 µM).  The target cells were also treated with 3TC (10 µM) 4 h 
prior to infection and 24 h post infection in the drug treatment groups.  (C) Measurement 
of virus titer.  The percent change in the virus titers of the wild-type and V223M mutant 
was measured in the absence or presence of 3TC (10 µM).  Two to four independent 
experiments were performed for NIH 3T3 and 143B cells.  Virus titers observed in the 
absence of 3TC treatment were defined as 100%.  Error bars represent the standard error. 
FIG. 2.  Structure of HIV-1-based constructs and activation of 3TC in NIH 
3T3, HeLA, 143B, and D17 cell lines.  (A) Structure of the HIV-1-based luciferase-
expression vector pNLuc, which contains both LTRs, other cis-acting elements required 
for viral replication, and the gag-pol gene of HIV-1.  pNLuc expresses the luciferase 
reporter gene (luc) from the LTR promoter.  (B) Experimental protocol.  The vectors 
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pNLuc and pSV-A-MLVenv were cotransfected into 293T cells and pseudotyped virus 
was used to infect various target cells (NIH 3T3, HeLA, 143B, and D17) for 4 h in the 
presence or absence of 3TC (10 µM).  The target cells were also treated with 3TC (10 
µM) 4 h prior to infection and 24 h post infection in the drug treatment groups.  (C) 
Measurement of chemiluminescence.  The percent of chemiluminescence was measured 
in the absence or presence of 3TC (10 µM).  At least two independent experiments were 
performed for NIH 3T3, HeLA, 143B, and D17 cells.  Chemiluminescence measurements 
in the absence of 3TC treatment were defined as 100%.  Error bars represent the standard 
error.  The standard error bars for both NIH 3T3 and HeLa are less than ± 0.3%  (not 
shown).    
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 Genetic variation of retroviruses.   The retroviruses and variation in retroviral 
population were discovered at the same time (42).  It has been observed that tumors, 
which resulted from infection by the same Rous sarcoma virus (RSV), possessed 
different morphology (18).  These morphological variations in tumors were correlated 
with genetic differences of RSV providing evidence of high genetic variation in retroviral 
populations (51).  Later, restriction digestion and sequencing techniques showed the 
existance of many closely related strains of MLV and spleen necrosis virus (SNV) (54).   
Additional evidence of retroviral genetic variation was the demonstration that passage of 
the same viral stock in tissue culture generated a pool of viruses with different RNase T1 
fingerprints (15).   A later work estimated the difference of the rate of nucleotide 
substitutions in a cellular gene versus viral genes.  It has been concluded that retroviral 
genes evolve at a rate one million times faster than cellular genes (20).  Now it appears 
that retroviruses are among the most diverse species in the world (12-14, 37).   
 It is important to study the mechanism that generate such a high genetic variation 
in retroviral populations, because it can provide evidence of how retroviruses escape the 
host immune response and develop drug resistance.   It has been postulated genetic 
variation of retroviruses is a result of a combination of a high replication rate, rapid 
turnover of productively infected cells, and high mutation and recombination rates (12-
14, 37).   
Mutation rates of retroviruses.  Many approaches were used to measure the mutation 
rate of RTs.  The most accurate way to estimate RT fidelity involves a forward mutation 
assay during single cycle of retroviral replication.   The mutation rates of RTs differs for 
different retroviruses and range from 0.1 to 3 × 10-5 mutations per base pair per 
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replication cycle (37). For RSV, the mutation rate was measured by harvesting virus from 
cell clones and infecting fresh target cells (30).  Viral RNA was analyzed by 
heteroduplex analysis.  Mutations were detected by altered pattern of band migration on a 
gel.  The mutation rate was estimated to be 1 × 10-4 mutations per base pair per 
replication cycle.  For MLV the mutation rate was measured by RNase T1-
oligonucleotide fingerprinting analysis of viral RNAs after one cycle of replication.  It 
was estimated to be 2 × 10-5 mutations per base pair per replication cycle.  An elegant 
method was employed to measure the mutation rate for SNV replication.  This method 
utilized a LacZα  peptide gene as a reporter of mutations that could be screened by 
blue/white phenotype.   The mutation rate was 1 × 10-5 mutations per basepair per 
replication cycle (38, 39).  Later, by utilizing the same approach the mutation rate was 
determined for HIV-1 to be 3 × 10-5 mutations per basepair per replication cycle (33).  
 Additionally, mutation rates of different mutant RTs, including drug-resistant 
mutants, were measured by different groups (5, 9, 10, 17, 21-23, 35, 36, 41, 43, 44, 49, 
52, 53).  Several in vitro studies indicated that some RT mutants displayed significantly 
higher fidelity than wild type the RT (5, 52, 53, 55).  These mutants include the primer 
grip mutants, 3TC-resistant variants of HIV-1 RT, as well as the E89G mutant.  This 
observation resulted in two hypotheses.   
First, it was hypothesized that increased fidelity of 3TC-resistant variant of HIV-1 
RT may account for lower emergence of virus in patients treated with 3TC, and for any 
delay of further resistance development for the other drugs (53).   Based on this 
hypothesis it was proposed that it might be beneficial to select for M184V 3TC-resistant 
virus strain (with a high fidelity RT) in a patient prior to starting the treatment with other 
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drugs.   However, several investigators have been able to show that 3TC-resistant virus 
strains harboring the M184V mutation easily mutate and are selected for double-drug 
resistance when put under treatment with other drugs (7, 8, 28).  The speed of emergence 
of these double mutant viruses proved not to be significantly different from wild type 
viruses exposed to the same drugs.  Also, the nature of mutations that were added to the 
M184V genetic background under drug treatment did not differ from those that were 
expected to appear in wild type virus under the same drug treatment.  Taken together 
these data suggested that the 3TC resistant variant of HIV-1 RT possesses fidelity similar 
to that of the wild type.  This result is in agreement with in vivo data from our laboratory, 
which indicate that the difference in fidelity between M and V variants of YVDD box of 
MLV RT is not more than two fold (22).   
Second, it has been proposed that RTs evolve to possess a suboptimal fidelity 
(55).  This suboptimal fidelity presumably is necessary for generation of retroviral 
genetic variation.  The current studies provide evidence against the theory of suboptimal 
fidelity of RTs.  We tested in vivo mutants of the primer grip that were previously shown 
to possess a higher fidelity in vitro.  In our in vivo assay these mutants resulted in a 
significant reduction of the viral titers (Chapter 3), suggesting that primer grip variants 
that perhaps possess a higher fidelity were not selected as a wild type not because these 
mutants could not generate retroviral genetic variation, but because these primer grip 
mutants could not support viral replication.  In addition, the overall data presented in the 
current study and other data from our laboratory indicated that among almost 100 MLV 
RT mutants generated, none of them displayed fidelity more than 30 % higher than wild 
type RT, suggesting that wild type RTs possesses an optimal fidelity.  However, it is 
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possible that we just did not make a mutation in MLV RT that could increase the 
accuracy of the DNA synthesis.   
To address this possibility we are planning to develop an in vivo assay for 
selection of MLV and HIV-1 RT variants that have a higher fidelity than wild type (Fig. 
1).  First, we will construct a retroviral vector that will encode for gag-pol proteins, as 
well as GFP-hygro fusion protein.  This retroviral vector will contain all cis elements 
necessary for retroviral replication including a packaging signal ψ.  The sequence of the 
pol gene that codes for RT will be randomized by PCR to ensure the presence of all 
possible RT mutants.  Second, we will construct two cell lines expressing two different 
envelopes.   The envelopes will be selected in such a way that self-reinfection of both cell 
lines will be prevented and virus produced by one cell line will be able to infect the other.  
The retroviral vector containing gag-pol and GFP-hygro genes will be infected at a low 
multiplicity of infection into one of the cell lines.  The low multiplicity of infection is 
necessary to ensure that each virus that will be produced from these infected cells will 
contain RT and a RNA genome transcribed from the same provirus.  Virus collected from 
the infected cell (infected cells will be sorted by FACS to select for infected cells that can 
produce virus to increase viral titer) and will be used to infect the other cell line.  Ping-
pong infections of fresh (uninfected) cells lines will be repeated several times and then 
followed by hygro selection and FACS to sort out the GFP positive cells.  A ping-pong 
infection is procedure in which two cell lines that express different viral envelope 
proteins and cocultivated.  As a result virus produced from each cell line effitiently infect 
the other cell line.  This procedure will allow us to select for RT mutants that did not 
introduce any inactivating mutations into GFP-hygro gene.  The overall procedure will be 
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repeated several times until mutant RT variants that possess a higher fidelity will appear.  
Sequencing the RT gene will reveal the genotype of this mutant(s).  A similar approach 
that employs a reversion mutation will be used to select for a mutant RT with a lower 
fidelity. 
Recombination of retroviruses.  Recombination of retroviruses also occurs at a high 
rate and contributes to the generation of genetic variation of retroviruses (1, 24, 25, 31, 
50).  Recombination rates of retroviruses have been measured by utilizing single cycle 
replication assays and were estimated to be around 4% per 1 kb per replication cycle (2).  
Although we did not measure the rate of recombination in this study, our data indicate 
that the rate of template switching events (including recombination) may be altered 
significantly by different factors (chapter 2).  One of the factors that could affect the 
frequency of template switching is the intracellular conditions such as presence of HU.  
The presence of HU altered the dNTP concentration in the cytoplasm and as a result 
decreased rate of DNA polymerization during reverse transcription (40).  The decreased 
rate of DNA polymerization caused the frequency of template switching to go up by 
approximately 2-fold.  These data should be taken in consideration when one proposes 
HU as an anti-retroviral agent.  Another factor that resulted in 5-fold increase in 
frequency of template switching is a single point mutation in the RT (chapter 1).  These 
data bring up an intriguing possibility that similar mutants play a role in generating 
genetic variation of retroviruses during the natural course of the retroviral replication.  If 
these mutation arise in viral populations, they may undergo extensive recombination and 
generate complex recombination.    More experimental evidence is required for 
investigating this possibility. 
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Previously, two models were proposed for retroviral recombination: forced copy-
choice model and strand displacement model (13, 26, 45).   Recent studies have favored 
the forced-copy choice model for retroviral recombination (2).    The forced copy-choice 
model proposes that a break in the viral RNA will force the RT to choose the other copy 
of the RNA genome and result in a recombination event.  In the current study we 
modified this model.  The new dynamic copy-choice model suggests that the driving 
force for switching templates is the formation of 3’ homology between newly synthesized 
DNA and the other copy of RNA (chapter 2, Fig. 6 in chapter 2).  
 Interestingly, the same model of template switching might be applied for the 
minus and plus strand transfer events.  If we assume that the RNA genome forms a 
structure inside of the viral core that by some reason brings two R regions together, the 
minus strand transfer event completely matches the proposed model for template 
switching (Fig. 2).  The homology of the R regions are necessary for formation of the 3’ 
homology between minus strand strong stop DNA and R region of the 3’ end of viral 
RNA.  This mechanism would suggest that there is no “JUMP” between the two ends of 
the viral RNA.  It is not clear if the disassociation of the tRNA from PBS takes place 
after minus strand transfer, however it would not be required for this model of strand 
transfer.  Even more, the tRNA-PBS interactions might be necessary to hold   the ends of 
RNA(DNA) template together for providing the plus strand transfer.  Again, the plus 
strand transfer may undergo the same mechanism of template switching (Fig. 2).   The 
only concern for the plus strand transfer is that length of homology for this template 
switch is as short as 18 nucleotides.  It is not known if these 18 nucleotides that are 
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associated with RT are available for interaction with the homologous sequence to form 
the 3’ interactions which were proposed to drive the switch.  
It has been very well established that the RNase H activity is important for strand 
transfer events in vivo and in vitro.  The in vivo the requirement for the RNase H activity 
was only demonstrated for the minus and plus strand transfer events (46, 48).  We 
demonstrate by the data presented in chapter 2 that RNase H activity is also important for 
other than minus and plus strand transfers in vivo, suggesting a similar mechanism of all 
template switches.  Future experiments are required to investigate whether 
polymerization dependent or polymerization independent (or may be both) RNase H 
activities play a role in template switching and recombination.   
The dynamic copy choice model was proposed by an interpretation that the 
dNTP-binding site mutants of MLV RT possess a slower polymerization rate than wild 
type RT, however it never was demonstrated directly.  Perhaps a real time PCR technique 
will help us to support this assumption.  Additionally, the role of other viral proteins, 
such as NC, for the frequency of the template switching could be tested by employing the 
assay developed in this study (chapter 2). 
Mechanism of fidelity of RT and other polymerases.  DNA polymerases make an error 
only once per 104-105 initial nucleotide incretions during DNA replication (34).  It is still 
not well understood how DNA polymerases select for incorporation of a correct base 
with such a high fidelity.  Both geometric effects and base-base hydrogen bonding have 
been thought to be important factors in DNA synthesis fidelity (19, 27, 32).  However, 
recently it has been demonstrated that formation of hydrogen bonds between incoming 
dNTP and a corresponding template base is not absolutely necessary for incorporation of 
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a correct dNTP (34).   The authors showed the analogs of dNTPs that possessed a similar 
shape but were not able to form hydrogen bonds could be successfully incorporated into 
DNA in accordance to their shape.   
 Two other recent studies have also provided interesting information about 
mechanisms of fidelity by DNA polymerases.  In these studies the crystal structures of T7 
DNA polymerase and Bacillus DNA polymerase were solved in a complex with 
template-primer (16, 29).  Both structures provided details of a sequence-independent 
molecular recognition of correctly formed base pairs.  Protein side-chains have been 
shown to interact in the minor groove of the first four base pairs extending from the 3’ 
primer terminus.  These highly conserved protein side chains or oriented water molecules 
anchored to protein side chain form hydrogen bonds to the N3 position of purine bases 
and O2 position of pyrimidine bases (16, 29, 47).  These interactions can occur only with 
correct Watson-Crick base pairs.  A mismatch could not bind with the same geometry as 
a correctly formed base-pair, resulting in misalignment of the 3’-OH primer terminus, 
thereby preventing incorporation of the next nucleotide.  As a consequence, the 
proofreading activity of these enzymes would remove an incorrect base and then continue 
the DNA synthesis.  At first glance, this mechanism of fidelity is not related to RT, 
because it was thought for a long time that RTs do not possess the proofreading.  
However, the AZT-resistance mechanism indicated that HIV-1 RT is able to remove the 
incorporated base (see details in chapter 1), suggesting that similar mechanism of fidelity 
could be considered (3, 4).  
 In chapter 3, we discuss how mutations of the minor groove binding helix affect 
the fidelity of the MLV RT.   Interestingly, the amino acids that we mutated are 
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contacting the second, third, and fourth nucleotide upstream of the 3’ OH of the primer 
(Fig. 6 in chapter 3).  Even though these amino acids do not contact the O2 and the N3 
positions of the nucleotide bases, mutations at these positions do affect fidelity up to 2.8-
fold.  The mechanism by which these residues of the thumb domain can influence the 
fidelity of RT remains to be determined.   
New approaches to overcome viral replication and drug-resistance.  Development of 
drug resistance depends on the presence of viruses that possess drug resistant mutations 
in the viral population at the time of the beginning of drug treatment (12, 14).  It would 
be interesting to identify the inhibitors of the drug-resistant HIV-1 RTs.  The easiest way 
would be to find an inhibitor to the 3TC-resistant HIV-1 RT, because resistance to 3TC is 
always associated with mutation at a single residue M184 of the YMDD motif (6).  A 
similar approach that was used for identifying the inhibitors of wild-type RT by using a 
massive screening of large number of compounds by relatively simple and possibly 
automated RT activity assays may be employed for identification of inhibitors of 3TC-
resistant RTs.  Once an inhibitor is found it could be introduced before (if a combination 
of inhibitors will result in a higher toxicity problem) or at the same time (if toxicity 
would not be a consideration) with 3TC.  Perhaps, introducing the new inhibitor of the 
3TC- resistant RT will slow down the development of 3TC resistance, because the 
number of drug resistant viruses that could replicate will be significantly reduced.  
Additionally, identification of an inhibitor against the drug-resistant variants may be 
beneficial for those HIV-1 infected patients that already carry the drug-resistant 
population as a result of monotherapy with 3TC.  In this situation, the introduction of 
other drugs targeted against different sites of RT or protease will not be useful because 
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the M184V viral population already contains all other mutations and is ready for 
development a new second drug resistance.  The approach of looking for drugs that can 
slow down the rate of infecting new cells (such as anti RT or protease) are important 
because they were shown to be able to reduce viral load to undetectable levels, and as a 
result, increase CD4 positive cell counts and improve the overall health of the patient.  
However, these drugs do not provide a long-term solution to the problem.  It was shown 
that even after a ten-year period of undetectable plasma virus, removal of the drug 
resulted in reemergence of the virus.  This virus seems to be a wild type (not drug-
resistant) virus that is probably present in a form of provirus in a long living cell 
reservoir.  It is not clear what kinds of cells constitute these reservoirs and what is the 
half-life time of cells.   
A different kind of approach perhaps could be utilized to address this problem.  
We do not have to wait for cells that carry a proviral DNA inserted in the cellular genome 
to die, but we can try to selectively kill these cells.  For example, a gene therapy approach 
could be employed.  We can create a virus that is pseudotyped with CD4 and CCR5 
proteins.  Presumably, this virus would be able to selectively infect cells that express the 
HIV-1 envelope proteins.  This virus could carry a retroviral vector that contains a DTA 
gene that is present in two separated fragments in LTRs.  Reverse transcription will result 
in reconstitution of the toxic gene and expresson of the toxic protein (11).  The cells that 
contain the proviral DNA will be selectively killed and the virus-containing reservoir will 
be eliminated.   
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Figure 1.  A schematic representation of in vivo assay to select for RT with a high 
fidelity.  
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Figure 2.  Template switching model for minus-strand and plus-strand transfers.  
Thin lane represents RNA; bold lane represents DNA; dashed lanes represent RNase H 
degradation.  Repeated sequences are shown as boxes.  
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FACS ANALYSIS DATA FOR POL + RNASE H DOUBLE 
MUTANTS, AND F156W AND RNASE H MUTANTS IN 
THE PRESENCE AND ABSENCE OF HYDROXYUREA 
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To test the dynamic-copy choice model for retroviral recombination proposed in 
Chapter 2, we performed additional analysis of MLV RT mutants.  First, we constructed 
double mutants containing mutations in the Pol as well as RNase H domains.  The V223I 
mutation in the active site of the Pol domain that increased the frequency of template 
switching by two-fold was combined with the Y598V RNase H mutant that decreased the 
frequency of template switching.  The V223I/Y598V double mutant exhibited the 
frequency of template switching similar to the RNase H mutant Y598V (Table 1 and Fig. 
1).  This result suggested that slowing down the rate of polymerization by approximately 
two-fold was not sufficient to rescue the RNase H defect of the Y598V mutant.  This 
result was consistent with previously observed results that slowing down polymerization 
by HU by approximately two-fold also did not rescue the defect of this RNase H mutant 
(Table 2, and Chapter 2).  We also constructed a double mutant that contained the F156W 
mutation in the Pol domain as well as Y598V mutation in the RNase H domain.  This 
mutant also did not show a statically significant effect on the frequency of template 
switching in comparison to the Y598V mutant (Table1 and Figure 1).  This result 
suggested that further slowing down the rate of polymerization still was not sufficient for 
rescuing the RNase H mutation defect.  Perhaps, the Y598V mutant possesses such a low 
RNase H activity that all direct repeat deletions occur during the plus-strand DNA 
synthesis. 
 To investigate whether any of the RNase H mutants could be rescued by the 
slowing down the rate of polymerization we performed the direct repeat deletion assay 
for the S526A and R657S RNase H mutants in the presence of HU.  The frequency of 
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template switching was not changed for the S526A mutant in the presence of HU, 
suggesting that HU did not rescue the defect of the S526A mutant (Table 2 and Figure 2). 
Interestingly, the R657S RNase H mutant displayed an increased frequency of template 
switching in the presence of HU (Table 2 and Figure 2).  This observation supported the 
dynamic copy-choice model proposed in Chapter 2.   
 Additionally, we tested the frequency of template switching of the F156W mutant 
in the presence of HU (Table 2 and Figure 2).  In presence of HU, the F156W mutant did 
not display a higher frequency of template switching than that observed previously in 
Chapter 2, suggesting that slower dNTP-binding in the presence of HU due to decreasing 
the nucleotide pool is not a rate limiting step in the case of F156W mutant.  It is possible 
that in case of the F156W mutant a step in catalysis that subsequent to the substrate dNTP 
binding is rate limiting. Surprisingly, the frequency of template switching by the F156W 
mutant in the absence of HU was higher than previously observed in Chapter 2.  This 
result could be explained by the fact that higher titers were obtained in the current 
experiment, which could produce a significant proportion of double-infected target cells 
and artificially increased the percent of the GFP positive cells.  
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TABLE 1.  Effect of mutations in MLV RT on the frequency of direct repeat 
deletion and GFP reconstitution  
                  MLV 
RT 
mutants 
 
No. of 
experiments 
 
Total no. of 
coloniesa  
Frequency of 
direct repeat 
deletions  
(mean % ± SE)b 
Relative change 
in direct repeat 
deletion 
frequencyc 
Wild type 5 > 3000 12.1 ± 0.9 1.0 
     
Y598V 3 > 1500   6.4 ± 0.2 0.5 
     
V223I 3 > 3000 30.5 ± 1.6 2.5 
     
F156W 5 > 5000 73.2 ± 2.2 6.0 
     
V223I / Y598V 3 > 1500  5. 2 ± 0.5 0.4 
     
F156W / Y598V 3 > 1500   9.2 ± 1.9 0.7 
a Total number of colonies analyzed by FACS in 3 to 5 independent infections.   
b Frequency of direct repeat deletion was determined as a percent of infected D17 
target cells that exhibited fluorescence after G418 selection compared to the negative 
control.  The standard error of the mean (SE) was determined by using the Sigma Plot 5.0 
program.  
c Calculated as follows: frequency of direct repeat deletion observed with mutant 
MLV RT ÷ frequency of direct repeat deletion observed with the wild-type RT.   
Statistically significant changes in the frequency of direct repeat deletions, relative to the 
wild-type RT (set to 1.0) are shown (two-sample t test: P < 0.05).   
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TABLE 2.  Effect of HU treatment on the frequency of direct repeat deletion and 
GFP reconstitution  
MLV RT 
mutants 
 
No. of 
experiments 
 
Total no. of 
coloniesa  
Frequency of 
direct repeat 
deletions  
(mean % ± SE)b 
Relative change 
in direct repeat 
deletion 
frequency c 
Wild type 5 > 3000 12.1 ± 0.9 1.0 
Wild Type + HU 4 > 2000 31.2 ± 0.8 2.5 
     
Y598V 3 > 1500   6.4 ± 0.2 1.0 
Y598V + HU 3   > 450   3.9 ± 0.8 none 
     
S256A 3 > 4000   6.1 ± 0.4 1.0 
S256A + HU 3 > 3000   7.6 ± 0.9 none 
     
R657S 6 > 5000   5.8 ± 0.4 1.0 
R657S + HU 6 > 2000   9.2 ± 0.6 1.5 
     
F156W  5 > 5000 73.2 ± 2.2 1.0 
F156W + HU 5 > 1400 54.2 ± 3.7 0.7 
a Total number of colonies that were analyzed by FACS in 3 to 6 independent 
infections.   
b Determined as for Table 1. 
c Calculated as follows: frequency of direct repeat deletion observed with mutant 
or wild-type MLV RT ÷ frequency of direct repeat deletion observed with the same MLV 
RT in the presence of 1 mM HU.  Statistical analysis using the two-sample t test showed 
that the wild-type, F156W, and R657S mutants of MLV RT displayed direct repeat 
deletion frequencies different from that observed in the presence of 1 mM HU (P < 0.01).  
The direct repeat deletion frequencies obtained with the Y598V and S526A mutants of 
MLV RT were not significantly different in the presence or absence of HU (P > 0.05). 
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Figure 1.  Effect of mutations in the MLV RT pol domain and RNase H domain on 
the frequency of GFP reconstitution.   The frequencies of GFP reconstitution were 
determined by FACS analysis. The results represent an average of 3 to 5 experiments, 
and the error bars represent the standard error of the mean. 
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Figure 2.  Effect of HU treatment on the frequencies of GFP reconstitution exhibited 
by the wild-type, and S526A, R657A, and F156W mutants of MLV RT.  Bars 
represent the frequencies of GFP reconstitution observed in the absence and presence of 
HU treatment as indicated.  The results represent an average of 3 to 6 experiments, and 
the error bars represent the standard error of the mean. 
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APPENDIX 2 
 
 
 
CONSTRUCTION OF THE THUMB DOMAIN AND 
PRIMER GRIP MLV RT MUTANTS  
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Thumb domain and primer grip MLV RT mutants utilized in the current study 
were generated by the PCR-based mutagenesis (Fig. 1).  The pES4 plasmid (Chapter 3) 
that expresses the gag-pol MLV proteins was employed as a template for mutagenesis.  
First, mutagenic primers with randomized nucleotides at positions corresponding to 
L269, R301, G305, F309, L312, or W313 and primers outside of the BamHI sites were 
used to amplify overlapping fragments containing mutations at the R301 position (primer 
sets: 1 and 2; 3 and 4 in Fig.1).  In addition, each mutagenic primer contained one or 
more silent mutations that resulted in the generation of a new restriction site.  All 
mutagenic primers with corresponding restriction sites are listed in Table 1.  Second, 
these two fragments were purified by elution from 1% agarose gels and annealed to each 
other by using the complementarity of the overlapping sequences.  Third, the annealed 
fragments were extended and PCR-amplifyed by utilizing outside primers (primers 1 and 
4).  The resultant PCR product was digested with BamHI and gel-purified.  These BamHI 
fragments containing mutations at positions L269, R301, G305, F309, L312, or W313 
were ligated with the wild type pES4 that was digested with BamHI.  Screening of the 
mutants was performed by utilizing new restriction sites that were generated during 
mutagenesis.  Correct orientation of the BamHI fragment as well as the overall structure 
of the mutant plasmid was confirmed by restriction enzyme digestion.  Additionally, the 
sequence between the BamHI sites as well as adjacent to the BamHI sites of all the 
mutant plasmids was also verified by sequencing.  The codons for all generated mutants 
are summarized in Table 2.  
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 TABLE 1.  Sequences of the primers utilized in generation of MLV RT mutants. 
 
Primer set Primer sequence (Mutated bases are shown in bold and new restriction sites are underlined)  
Restriction 
site 
generated 
Outside 
primer 1 
(For) 
5’- GTCAACAAGCGGGTGGAAGACATCC -3’ NONE 
Outside 
primer 4 
(Rev) 
5’- CACCGGCCGACGCCAAGGTCCCAG -3’ NONE 
L269XFor 5’- CAGAAACAGGTCAAGTATNNSGGGTACCTT CTAAAAGAGGGTC -3’ KpnI 
L269XRev 5’- GACCCTCTTTTAGAAGGTACCCSNNATACTT GACCTGTTTCTG -3’ KpnI 
R301XFor 5’- CGAAGACCCCTCGACAACTANNNGAATTCCTAG GGACGGC - 3’ EcoRI 
R301XRev 5’- GCCGTCCCTAGGAATTCNNNTAGTTGTCGAGGG GTCTTCG -3’ EcoRI 
G305XFor 5’- CGACAACTAAGGGAATTCCTANNNACGGCAGG CTTCTGTCG -3’ EcoRI 
G305XRev 5’- CGACAGAAGCCTGCCGTNNNTAGGAATTCCCTT AGTTGTCG -3’ EcoRI 
F309XFor 5’- CCTAGGGACTGCAGGCVNNTGTCGCCTCTGGA TC -3’ PstI 
F309XRev 5’- GATCCAGAGGCGACANNBGCCTGCAGTCCCTA GG -3’ PstI 
L312XFor 5’- GGGACGGCAGGCTTCTGCAGANNNTGGATCCC TGGGTTTGC -3’ PstI 
L312XRev 5’- GCAAACCCAGGGATCCANNNTCTGCAGAAGCC TGCCGTCCC -3’ PstI 
W313XFor 5’- GGGACGGCAGGCTTCTGCAGACTCNNNATCCC TGGGTTTGC -3’ PstI 
W313XRev 5’- GCAAACCCAGGGATNNNGAGTCTGCAGAAGCC TGCCTACCATCCC -3’ PstI 
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TABLE 2.  Codons of the generated mutants.  
 
  
Mutant Codon Mutant Codon Mutant Codon 
L269 (WT) CTG R301 (WT) AGG G305 (WT) GGG 
L269A GCC R301H CAC G305D GAT 
L269G GGG R301I ATT G305E GAG 
L269H CAC R301L TTG G305F TTC 
L269N AAC R301P CCA G305I ATT 
L269Q CAG R301Q CAG G305N AAT 
L269R CGG R301S TCA G305Q CAG 
L269S TCA R301V GTC G305R CGG 
L269T ACG   G305V GTC 
 
 
 
Mutant Codon Mutant Codon Mutant Codon 
F309 (WT) TTC L312 (WT) CTC W313 (WT) TGG 
F309A GCC L312E GAG W313A GCT 
F309H CAC L312R CGG W313D GAT 
F309I ATT   W313Q CAA 
F309L CTA     
F309N AAT     
F309P CCA     
F309T ACA     
F309V GTT     
F309W TGG     
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Figure 1.  PCR-based mutagenesis protocol.  Lines represent DNA; bold arrows 
represent primers; filled circles represent mutations.   
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